REGULATION OF 15-LIPOXYGENASE AND CHARACTERISATION OF THE LIPOXIN/RESOLVIN RECEPTOR by CHRISTABEL HO FUNG-YIH
REGULATION OF 15-LIPOXYGENASE AND 





CHRISTABEL HO FUNG-YIH 






A THESIS SUBMITTED FOR THE DEGREE OF 




DEPARTMENT OF ANATOMY 
YONG LOO LIN SCHOOL OF MEDICINE 












I hereby declare that this thesis is my original work and it has been 
written by me in its entirety. I have duly acknowledged all the 
sources 
of information which have been used in the thesis. 
 







Christabel Ho Fung-Yih 














I would like to take this opportunity to extend my deepest gratitude to 
my two supervisors, Associate Professor Ng Yee Kong and Associate 
Professor Ong Wei Yi (Department of Anatomy, Yong Loo Lin School of 
Medicine, National University of Singapore) for all their guidance, help and 
encouragement throughout my candidature. Their support and advice have 
been invaluable in the accomplishment of this thesis. I would also like to thank 
the current and previous Head of the Department of Anatomy, Associate 
Professor S Thameem Dheen and Professor Bay Boon Huat, respectively, 
for providing me the opportunity to take on my postgraduate studies in the 
department.  
I would like to extend my appreciation to Dr. Lin Teng-Nan (Faculty 
of Neuroscience, Institute of Biomedical Sciences, Academia Sinica, Taiwan) 
for his kind assistance with the experimental work, and to Dr. Wu Ya Jun 
(Department of Anatomy, Yong Loo Lin School of Medicine, National 
University of Singapore) for her help with electron microscopy. 
I wish to express my greatest appreciation to my colleagues and 
mentors, past and present, for their support and help throughout my 
candidature: Dr. Chew Wee Siong, Dr. Loke Sau Yeen, Shalini D/O Suku 
Maran, Tan Siew Hon Charlene and Tan Wee Shan Joey. I would also like 
to express my utmost gratitude to my peer, Tan Hui Ru Laura. Her 
companionship and timely advice kept me going and it was enjoyable working 




I would also like to thank my family and friends for their continuous 
support and encouragement. Last but not least, I give my utmost thanks and 
praise to the Lord Jesus Christ, for with His grace and providence was I able 












Table of Contents 
V 
 




Declaration Page II 
Acknowledgements III 
Table of Contents V 
Summary X 
List of Tables XII 
List of Figures XIII 
List of Abbreviations XV 
  
SECTION I - INTRODUCTION 1 
1.0   Neurodegeneration 2 
1.1   Acute neuroinflammation 3 
1.2   Chronic neuroinflammation and neurodegeneration  4 
  
2.0   Lipoxygenases 6 
2.1   Arachidonate 5-Lipoxygenase 7 
2.2   Arachidonate 12-Lipoxygenase 9 
2.3   Arachidonate 15-Lipoxygenase 11 
2.3.1   15-Lipoxygenase-2 11 
2.3.2   15-Lipoxygenase-1 (15-LOX-1) 12 
 2.3.2.1   Structure and activity 12 
2.3.2.2   Biological roles of 15-LOX-1 and its 
metabolites 
15 
2.3.2.3   15-LOX-1 in the brain 16 
2.4   Pathological roles of 15-LOX-1 17 
2.4.1   15-LOX-1 in carcinogenesis 17 
2.4.2   15-LOX-1 in inflammation 18 
2.4.3   15-LOX-1 in neuroinflammation and 
neurodegeneration 
20 
3.0   Epigenetics 23 
Table of Contents 
VI 
 
3.1   Histone modifications 24 
3.1.1   Histone acetyltransferases (HATs)  26 
3.1.2   Histone deacetylases (HDACs)  28 
3.1.3   Histone methyltransferases (HMTs) 30 
3.2   Epigenetics and neuroinflammation 31 
3.3   Epigenetics and neurodegenerative diseases 32 
  
4.0   Formyl-peptide receptors 34 
4.1   Formyl-peptide receptor 2 (FPR2) 35 
4.1.1   Multi-ligand nature of FPR2 36 




SECTION II – AIMS OF STUDY 41 
  
SECTION III – EXPERIMENTAL STUDY 44 
CHAPTER I – 15-LIPOXYGENASE IN THE CNS 
 
45 
1.1   Introduction 46 
1.2   Materials and Methods 48 
1.2.1   Chemicals 48 
1.2.2   Animals 48 
1.2.3   Real-Time Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) 
48 
1.2.4   Western Blot 49 
1.2.5   Immunohistochemistry 51 
1.2.6   Transmission Electron Microscopy 52 
1.2.7   Liquid Chromatography Mass Spectrometry (LC-
MS) 
52 
1.3   Results 54 
1.3.1   Differential expression of LOX isoforms in the 
CNS 
54 
1.3.2   Western Blot analyses of 15-LOX-1 protein 
expression in the CNS 
56 
Table of Contents 
VII 
 
1.3.3   15-LOX-1 localisation in forebrain under light 
microscopy 
58 
1.3.4   15-LOX-1 localisation in hindbrain and spinal 
cord under light microscopy 
59 
1.3.5   15-LOX-1 localisation in the prefrontal cortex and 
hippocampus under transmission electron 
microscopy 
60 
1.3.6   LC-MS analyses of resolvin D1 levels in the rat 
PFC after 15-LOX-1 inhibition 
61 
1.4   Discussion 62 
  




2.1   Introduction 68 
2.2   Materials and Methods 70 
2.2.1   Materials 70 
2.2.2   Cell culture 70 
2.2.3   Primary neuron culture 71 
2.2.3.1   Treatment of primary neurons with HAT 
and HDAC inhibitors 
71 
2.2.3.2   Semi-quantitative Reverse Transcriptase 
Polymerase Chain Reaction (RT-PCR) 
71 
2.2.3.3   Western Blot 72 
2.2.4   SH-SY5Y cell culture 73 
2.2.4.1   Treatment of SH-SY5Y cells with HDAC 
inhibitors 
73 
2.2.4.2   Treatment of SH-SY5Y cells with HAT 
inhibitors and TSA 
73 
2.2.4.3   Treatment of SH-SY5Y cells with HAT 
inhibitors and NaBT 
73 
2.2.4.4   Treatment of SH-SY5Y cells with HAT 
inhibitors and MS-275 
74 
2.2.4.5   Treatment of SH-SY5Y cells with HAT 74 
Table of Contents 
VIII 
 
inhibitors and depsipeptide 
2.2.4.6   Treatment of SH-SY5Y cells with MTA 
and TSA 
74 
2.2.5   Real-Time Reverse Transcriptase Polymerase 
Chain Reaction (qRT-PCR) 
75 
2.2.6   Immunocytochemistry 76 
2.2.7   Quantitative image analysis 76 
2.2.8   Lactate dehydrogenase (LDH) assay 77 
2.3   Results 79 
2.3.1   Effect of HAT and HDAC inhibitors on 15-LOX-1 
expression in primary cortical neurons 
79 
2.3.2   Effect of HDAC inhibitors on 15-LOX-1 
expression in SH-SY5Y cells 
81 
2.3.3   Effect of MB-3 and TSA on 15-LOX-1 expression 
in SH-SY5Y cells 
82 
2.3.4   Effect of NU9056 and TSA on 15-LOX-1 
expression in SH-SY5Y cells 
83 
2.3.5   Effect of C646 and TSA on 15-LOX-1 expression 
in SH-SY5Y cells 
85 
2.3.6   Effect of NU9056 and NaBT on 15-LOX-1 
expression in SH-SY5Y cells 
87 
2.3.7   Effect of C646 and NaBT on 15-LOX-1 
expression in SH-SY5Y cells 
87 
2.3.8   Effect of HAT inhibitors and MS-275 or 
depsipeptide on 15-LOX-1 expression in SH-
SY5Y cells 
89 
2.3.9   Effect of MTA and TSA on 15-LOX-1 expression 
in SH-SY5Y cells 
90 
2.3.10  Lactate dehydrogenase assay 92 
2.4   Discussion 94 
  
CHAPTER III – CHARACTERISATION OF THE LIPOXIN 
/RESOLVIN RECEPTOR FORMYL-PEPTIDE RECEPTOR 2 
IN THE RAT CNS 
100 




3.1   Introduction 101 
3.2   Materials and Methods 104 
3.2.1   Animals 104 
3.2.2   Real-Time Reverse Transcriptase Polymerase 
Chain Reaction (RT-PCR) 
104 
3.2.3   Western Blot 105 
3.2.4   Immunohistochemistry 107 
3.2.5   Transmission Electron Microscopy 108 
3.3   Results 109 
3.3.1   Differential expression of FPR2 mRNA in the rat 
CNS 
109 
3.3.2   Western Blot analyses of FPR2 protein expression 
in the rat CNS 
110 
3.3.3   FPR2 localisation in forebrain under light 
microscopy 
112 
3.3.4   FPR2 localisation in hindbrain and spinal cord 
under light microscopy 
114 
3.3.5   FPR2 localisation in the prefrontal cortex under 
transmission electron microscopy 
116 
3.4   Discussion 117 
  
SECTION IV – CONCLUSION 125 
  





 Arachidonic acid and docosahexaenoic acid (DHA) are important 
polyunsaturated fatty acids (PUFA) in the central nervous system (CNS). 15-
lipoxygenase-1 (15-LOX-1) is an enzyme that can metabolise arachidonic acid 
and DHA to produce various neuroprotective lipid mediators such as lipoxin 
A4 (LXA4), resolvin D1 (RvD1) and neuroprotectin D1. Given the importance 
of 15-LOX-1, however, little is known about its distribution and epigenetic 
regulation in the CNS. 
 In the first chapter, the expression, distribution and localisation of 15-
LOX-1 in the CNS is elucidated through real-time reverse transcription 
polymerase chain reaction (RT-PCR), Western blot and 
immunohistochemistry. 15-LOX-1 was found to be highly expressed in the 
forebrain, particularly the prefrontal cortex. Upon examination with electron 
microscopy techniques, 15-LOX-1 was found to be localised in the dendrites 
of postsynaptic neurons and axons of presynaptic neurons. Lipid analyses 
revealed decreased levels of RvD1 in the prefrontal cortex after 15-LOX-1 
inhibition. The distribution and localisation of 15-LOX-1 may explain certain 
effects of DHA in the CNS. 
 In the second chapter, the differential epigenetic regulation of 15-
LOX-1 in differentiated primary neurons and undifferentiated neuronal-like 
SH-SY5Y cells is examined. Treatment with the general histone deacetylase 
(HDAC) inhibitor TSA and specific p300 or Tip60 histone acetyltransferase 
(HAT) inhibitors revealed that 15-LOX-1 is insensitive to epigenetic 




LOX-1 expression in undifferentiated neuronal-like SH-SY5Y cells was 
observed after treatment with general and specific HDAC inhibitors, showing 
that 15-LOX-1 is highly sensitive to epigenetic modifications in 
undifferentiated neuronal-like cells. Pretreatment with p300 or Tip60 HAT 
inhibitors before HDAC inhibitors demonstrated that 15-LOX-1 expression is 
regulated together by HATs and HDACs in undifferentiated SH-SY5Y cells. 
In SH-SY5Y cells, TSA caused cell death through increased release of LDH; 
however, pretreatment with PD146176 revealed that 15-LOX-1 is likely not 
involved in TSA-mediated cell death. Findings suggest 15-LOX-1 is 
epigenetically regulated in undifferentiated neuronal-like SH-SY5Y cells but 
not so in differentiated primary neurons. 
 In the third chapter, the LXA4/RvD1 receptor, formyl-peptide receptor 
2 (FPR2) is characterised in the CNS. Through RT-PCR, Western blot and 
immunohistochemistry, FPR2 was found to be expressed in the CNS, 
particularly in the brainstem and spinal cord. Furthermore, FPR2 was localised 
on the immature axon terminals and dendrites of neurons. The expression of 
FPR2 in the CNS may help to explain how LXA4 and RvD1 mediate their 
neuroprotective effects in the CNS. 
 Together, these findings may provide further understanding of 15-
LOX-1, its activity on DHA whose products are agonists at FPR2, and their 
effects in the CNS. Furthermore, elucidation of the epigenetic regulation of 
15-LOX-1 presents a deeper insight into transcriptional mechanisms of 15-
LOX-1 in neurons and its effects in the developing brain. 
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 Neuroinflammation is defined as a process in the central nervous 
system (CNS) whereby immune cells are recruited and activated during tissue 
injury or infection, releasing various pro-inflammatory mediators. The 
inflammatory response consists of a pro-inflammatory phase in which 
pathogens, damaged cells and debris are cleared, and the local homeostasis 
restored. Thereafter, there is a phase of resolution which is driven by 
progressively decreasing levels of pro-inflammatory mediators over time 
(Kohli and Levy 2009) and involves cellular mechanisms such as cell 
clearance from tissues by inflammatory cell apoptosis (Rossi et al. 2006) and 
local tissue repair (Medzhitov 2008; Serhan et al. 2008). The brain is an 
immune-privileged site due to its isolation from the peripheral immune system 
by the blood-brain barrier, allowing inflammation to be tightly regulated. 
Resident immune cells of the CNS are known as microglia, a form of glial 
cells, which are responsible for regulating inflammation in the brain. Besides 
microglia, there is increasing evidence for the role of astrocytes, another type 
of glial cell, in the local innate immune response. Astrocytes express class II 
major histocompatibility complex antigens and co-stimulatory molecules that 
are essential for antigen presentation and T-cell activation (Dong and 
Benveniste 2001) and can express cytokines and chemokines such as 
interleukin-6 (IL-6) (Van Wagoner and Benveniste 1999). Factors released by 
astrocytes such as granulocyte-macrophage colony-stimulating factor (GM-
CSF), IL-6, and chemokines CCL2 and CCL5 regulate microglial migration, 
activation and proliferation (Farina et al. 2007). Both microglia and astrocytes 





pro-inflammatory mediators and contributing to the inflamed state (Gao et al. 
2013; Goldmann and Prinz 2013). There are two forms of neuroinflammation 
classified based on their duration: acute and chronic. 
 
1.1 Acute neuroinflammation 
Under normal conditions, microglia are usually in a resting state and 
constantly surveying their surroundings for foreign material (Nimmerjahn et al. 
2005). When microglia come into contact with damaged neurons, plaques or 
pathogens, they become activated. This activation encompasses a change in 
morphology and microglia proliferation. Activated microglia then migrate to 
the site of damage where they phagocytose pathogens and clear cellular debris 
(Aloisi 2001). Activated microglia release pro-inflammatory mediators such as 
cytokines, nitric oxide and reactive oxygen species (ROS) as part of their 
inflammatory response. High levels of IL-6 are predominantly released by 
activated astrocytes during brain injury, trauma, stroke and inflammation, 
leading to neurodegeneration and breakdown of the blood-brain barrier (Van 
Wagoner and Benveniste 1999). Secretion of chemokines from astrocytes 
allows the chemotaxis of T-cells, B-cells and granulocytes into the brain 
parenchyma (Jensen et al. 2013). 
However, microglia can take part in the resolution of inflammation 
through the production of anti-inflammatory mediators such as IL-10 (Cherry 
et al. 2014). Additionally, in the case of neuronal damage, activated microglia 
can promote repair and re-growth of neurons (Trapp et al. 2007). Astrocytes 
can also counteract the pro-inflammatory response from microglia (Pratt and 





population and provide neurotrophic factors to stressed neuronal cells (Rossi 
et al. 2007). In addition, reactive astrocytes can potently inhibit the cytokine 
response of microglia to inflammatory stimuli (Kostianovsky et al. 2008) and 
secrete neurotrophic factors for neuronal recovery and survival (Escartin and 
Bonvento 2008). Acute neuroinflammation is short-lasting and subsides after 
the elimination of tissue-damaging factors (Nikbin et al. 2011). Therefore, 
acute neuroinflammation is essential for a healthy CNS by maintaining the 
local homeostasis and providing neuroprotection.  
 
1.2 Chronic neuroinflammation and neurodegeneration 
 In contrast to acute neuroinflammation, chronic neuroinflammation is 
characterised by long-lasting, persistent inflammation in the brain. In chronic 
inflammation, microglia are over-activated and contribute to a chronic pro-
inflammatory state by sustained production of pro-inflammatory mediators, 
resulting in tissue damage and neuronal death over time. The role of 
chronically activated microglia in neurodegeneration is well-established over 
the years, where they are known to contribute to neuronal dysfunction, injury 
(Chao et al. 1992), and loss (Boje and Arora 1992) leading to disease 
progression (Streit et al. 2004). Microglial activation may also be a response to 
neuronal dysfunction and the low activation threshold of microglia leads to 
them usually being involved in brain injuries or pathologies. Therefore, 
widespread microglial activation may reflect extensive neuronal dysfunction 
as seen in neurodegenerative diseases (Graeber et al. 2011). 
Various in vitro studies have shown that microglia are able to 





et al. 1997; Chung et al. 1999). However, in Alzheimer’s disease (AD), 
microglial clearance of Aβ is either ineffective or inadequate (Streit et al. 2004) 
and degradation can be hindered when Aβ accumulates (Paresce et al. 1997). 
In fact, aggregation of Aβ plaques around neurons causes microglia to 
surround these plaques and become activated, perpetuating neuronal damage 
and death (Meda et al. 1995; Sasaki et al. 1997). Activated microglia are also 
observed in the substantia nigra of Parkinson’s disease (PD) mouse models 
(Czlonkowska et al. 1996), living PD patients (Ouchi et al. 2005) and post-









 Lipoxygenases (LOXs) are a family of lipid peroxidising enzymes that 
catalyse the insertion of dioxygen at specific carbons of polyunsaturated fatty 
acids (PUFAs). The general LOX molecular structure consists of one non-
heme iron at its catalytic site, while four histidines (H361, H366, H541, H545) 
and one isoleucine at the C-terminal constitute the protein iron ligands (Kuhn 
et al. 2002). These enzymes act on PUFAs to generate hydroxyperoxide 
products that may act as signalling molecules or induce structural or 
physiological changes in the cell. LOXs are widely distributed and highly 
conserved enzymes found in both animals and plants. Traditionally, 
mammalian LOXs have been named according to their reaction specificity 
using arachidonic acid. 5-, 12- and 15-lipoxygenases are, thus, named 
according to the carbon position at which they catalyse the insertion of 
molecular oxygen (Kuhn et al. 2002). Six human lipoxygenase genes - 
ALOX5, ALOX12, ALOX12B, ALOX15, ALOX15B and ALOXE3 – 
encoding six different isoforms have been elucidated (Funk et al. 2002). 
Arachidonic acid (n-6), linoleic acid (n-6), alpha- (n-3) and gamma- (n-6) 
linolenic acid, eicosapentaenoic acid (EPA, n-3) and docosahexaenoic acid 
(DHA, n-3) are the most abundant PUFAs that can be metabolised by LOXs 
(Ivanov et al. 2015). As PUFAs are esterified to the sn-2 position of 
membrane phospholipids, the action of ester lipid hydrolysing enzymes such 
as cytosolic phospholipase A2 (cPLA2) or by the combined actions of 
phospholipase C and diacylglycerol kinase, or phospholipase D and PLA2, are 
necessary for their release (Needleman et al. 1986; Sun et al. 2010). The LOX 





known as hydroperoxyeicosatetraenoic acids (HPETEs), which are 
subsequently converted to hydroxyicosatetraenoic acids (HETEs). The 
hydroxyperoxide products formed by the different LOX isoforms are 
subsequently converted, via different pathways, to various bioactive lipid 
mediators. The LOX metabolism of linoleic acid differs in the way that it 
results in production of hydroxyoctadecadienoic acids (HODEs) instead (Funk 
1993). It is possible for LOXs to work consecutively to generate products that 
differ from those produced solely by those LOXs. Such a phenomenon is 
termed as transcellular metabolism, a process whereby a cell with one type of 
LOX can produce a certain intermediate and export it to a different cell with 
another type of LOX that will further metabolise the intermediate to generate a 
final product (Gijon et al. 2007). An example of this is the production of 
lipoxins, which requires the activities of both 15-lipoxygenase and 5-
lipoxygenase (Serhan et al. 1984). 
  
2.1 Arachidonate 5-Lipoxygenase 
 The arachidonate 5-lipoxygenase (5-LOX) gene (ALOX5) is located 
on chromosome 10 and contains 14 exons (Funk et al. 1989). Its transcribed 
protein consists of 673 amino acids and has a molecular weight of 
approximately 78 kDa (Matsumoto et al. 1988). The enzyme requires both 
calcium ions and ATP for its enzymatic activity. 5-LOX is anchored to the cell 
membrane by a protein known as 5-lipoxygenase-activating protein (FLAP), 
allowing it to carry out its enzymatic activity. 5-LOX acts on arachidonic acid 
released from membrane phospholipids by the catalytic action of cPLA2, 





and its subsequent conversion to leukotriene A4, a pro-inflammatory mediator. 
Leukotriene A4 may then be further metabolised to generate leukotrienes B4, 
C4, D4 and E4 (Fabre et al. 2002). 5-LOX, together with 15-lipoxygenase, is 
also involved in production of anti-inflammatory and pro-resolving lipid 
mediators known as lipoxins. 
 5-LOX is present in glial cells and neurons, where it is expressed in the 
cytosol and nucleus or only in the cytosol (Zhang et al. 2006). 5-LOX has 
been suggested to play a role in neuronal development. In vitro, a higher 
expression of 5-LOX has been observed in developing neurons but not in the 
mature phenotype (Manev and Uz 1999). In addition, 5-LOX inhibition in 
developing neurons resulted in cell death, which was not observed in mature 
neurons (Manev et al. 2000). Besides the pro-inflammatory nature of 
leukotrienes, these lipid mediators may have other biological effects as 
demonstrated by the presentation of a fatal developmental and neurological 
syndrome caused by an inability to synthesise leukotrienes de novo 
(Mayatepek and Flock 1998). 
The 5-LOX pathway is highly indicated in neurodegeneration due to its 
pro-inflammatory activities. 5-LOX is widely expressed in cerebral neurons, 
especially in the hippocampus and cerebellum (Lammers et al. 1996). Its 
expression in neurons increases with ageing (Uz et al. 1998; Manev et al. 2000) 
and may be involved in ageing-associated neurodegenerative diseases. Higher 
levels of 5-LOX and leukotriene A4 were observed in the hippocampi of older 
mice (Chinnici et al. 2007), suggesting a link between inflammation and 
possible hippocampal dysfunction. Overexpressed or overactive 5-LOX may 





higher levels of 5-LOX in neurons compared to young rats, coupled with an 
increased susceptibility to excitotoxic brain injury (Uz et al. 1998). 
Mobilisation and activation of neuronal 5-LOX was also observed in the 
brain’s response to ischaemia (Ohtsuki et al. 1995; Zhou et al. 2006). 5-LOX 
was found to be upregulated in glial cells and neutrophils after traumatic brain 
injury (Zhang et al. 2006). 5-LOX is highly indicated in the pathophysiology 
of AD. It was found to be expressed in higher levels in the hippocampal 
neurons of human Alzheimer brains (Ikonomovic et al. 2008). Overexpression 
of 5-LOX raises Aβ levels in vitro and is correlated with an increase in 
expression of γ-secretase (Chu and Pratico 2011). 5-LOX inhibition in vitro 
decreases Aβ production and transgenic mice lacking 5-LOX (Firuzi et al. 
2008) or given a 5-LOX inhibitor (Chu and Pratico 2011) demonstrated 
decreased brain Aβ deposition. 5-LOX-deficient mice and mice treated with 
the same 5-LOX inhibitor demonstrated significant memory improvements, 
recovered synaptic function and improved synaptic integrity, suggesting a role 
of 5-LOX in synaptic plasticity and memory (Giannopoulos et al. 2014).  
 
2.2 Arachidonate 12-Lipoxygenase 
 The arachidonate 12-lipoxygenase (12-LOX) gene (ALOX12) is 
localised on chromosome 17 and encodes a protein of 663 amino acids with a 
molecular weight of approximately 75 kDa (Tang and Honn 2012). Three 
isoforms of 12-LOX have been reported in mammals, namely the platelet 
(Hamberg and Samuelsson 1974; Nugteren 1975; Takahashi et al. 1993), 
leukocyte (Yoshimoto et al. 1982), and epidermal types (Funk et al. 1996). 





immunoreactivity (Funk 1996; Brash 1999). The platelet type 12-LOX 
metabolises only arachidonic acid to release 12S-hydroperoxyeicosatetraenoic 
acid (12S-HPETE) which is then converted to 12S-hydroxyeicosatetraenoic 
acid (12S-HETE) (Yoshimoto and Yamamoto 1995; Funk 1996; Brash 1999). 
Leukocyte-type 12-LOX metabolises both arachidonic acid and linoleic acid 
to generate 12S-HETE and small amounts of 15S-hydroxyicosatetraenoic acid 
(15S-HETE). 
There is evidence for leukocyte-type 12-LOX in the brain (Nishiyama 
et al. 1993; Chinnici et al. 2005) and in cultured neurons (Palluy et al. 1994). 
12-HETE is a mediator of synaptic modulation and is reported to be a second 
messenger for presynaptic inhibition (Piomelli et al. 1987a; Piomelli et al. 
1987b). It may also be involved in learning and memory as a messenger in 
long-term potentiation (Palluy et al. 1994). Due to the pro-inflammatory 
nature of 12-LOX and its products (Bleich et al. 1995; Chen et al. 2005; 
Chakrabarti et al. 2009), this enzyme has been implicated in various brain 
pathologies. 12-LOX is upregulated in human Alzheimer brain samples 
together with higher levels of its metabolic products, and is associated with 
brain lipid peroxidation (Pratico et al. 2004). Furthermore, 12-LOX and 12-
HETE were shown to cause Aβ-associated apoptosis of cortical neurons by 
overexpressing c-Jun (Lebeau et al. 2004). Additionally, 12-LOX modulates 
Aβ (Chu et al. 2012), amyloid precursor protein (APP) metabolism (Succol 
and Pratico 2007) and tau protein metabolism (Giannopoulos et al. 2013). 
Loss of glutathione as seen in PD causes the activation of 12-LOX, leading to 






2.3 Arachidonate 15-Lipoxygenase 
The 15-LOX gene (ALOX15) is located on chromosome 17. There 
exists two isoforms of 15-LOX: reticulocyte-type 15-LOX (15-LOX-1), 
encoded by the ALOX15 gene, and epidermis-type 15-LOX (15-LOX-2), 
encoded by the ALOX15B gene. 15-LOX-1 and 15-LOX-2 share little 
sequence homology, and as they differ in their preferential substrates, they 
have different properties and roles (Kuhn et al. 2002). 15-LOX acts on a 
variety of substrates including linoleic acid, alpha- and gamma-linolenic acid, 
arachidonic acid, EPA, and DHA.  
 
2.3.1 15-Lipoxygenase-2 
 15-LOX-2 is encoded by the ALOX15B gene. Its protein is 676 amino 
acids-long and has a molecular weight of 76 kDa (Kuhn et al. 2002). The 
amino acid sequence of 15-LOX-2 is only 40% similar compared to that of 15-
LOX-1, and its distribution is limited to the skin, lung, prostate, and cornea 
(Brash et al. 1997). It was not detected in the brain (Brash et al. 1997). 15-
LOX-2 metabolises arachidonic acid almost exclusively to 15S-
hydroperoxyeicosatetraenoic acid (15S-HPETE) which is then reduced to 15S-
HETE. It metabolises linoleic acid less effectively than 15-LOX-1, producing 
13S-hydroperoxyoctadecadienoic acid (13S-HPODE) which is rapidly reduced 
to 13S-hydroxyoctadecadienoic acid (13S-HODE) (Brash et al. 1997). 15-
LOX-2 is highly indicated in carcinogenesis and is believed to be a prostate 
tumour suppressor given its loss of expression in various prostate carcinomas 






2.3.2  15-Lipoxygenase-1 (15-LOX-1) 
2.3.2.1  Structure and activity 
15-LOX-1 was first described in 1975 in rabbit reticulocytes (Schewe 
et al. 1975). It is well-characterised (Rapoport et al. 1979) and led to further 
discoveries of this enzyme in other mammalian species. Human 15-LOX-1 
was discovered in human eosinophils a few years later (Sigal et al. 1988). The 
human 15-LOX-1 gene is located on the short arm of chromosome 17 and 
consists of 14 exons and 13 introns (Ivanov et al. 2015). Promoter studies of 
this gene revealed potential binding sites for various transcription factors 
(Kelavkar et al. 1998). In human ALOX15, these binding sites were localised 
to between 20 kb upstream and 10 kb downstream of the transcription 
initiation site (Ivanov et al. 2015). Studies of the human 15-LOX-1 
complementary DNA (cDNA) reveal that its mRNA is made of 2700 bases, of 
which 28 bases make up the 5’-untranslated region (5’-UTR) and 704 bases in 
the 3’-UTR. A cytidine-rich repetitive motif near the stop codon at the 3’-UTR 
known as the differentiation control element (DICE) is crucial for the 
maturation-dependent expression regulation of 15-LOX-1 (Reimann et al. 
2002). Compared to rabbit 15-LOX, the DICE motif is truncated in human 15-
LOX-1 (Ivanov et al. 2015).  
Human 15-LOX-1 protein is a single polypeptide of 662 amino acids 
with a molecular weight of 75 kDa. Murine 15-LOX-1 mRNA is similar to its 
human orthologue but only has 75% amino acid sequence similarity (Ivanov et 
al. 2015). The crystal structure of rabbit 15-LOX-1 revealed that mammalian 
15-LOX-1 consists of two domains. The small N-terminal domain of 110 





in membrane binding of the enzyme. The larger C-terminal domain contains 
the catalytic non-heme iron and is made of 18 helices by a small β-sheet sub-
domain (Gillmor et al. 1997). The core of the catalytic C-terminal domain 
contains two long central helices, one of which adopts a π-helix conformation. 
This π-helical section contains four histidines that make up the protein iron 
ligands. The fifth protein iron ligand is an isoleucine residue. The substrate 
binding cleft of 15-LOX-1 is a boot-shaped cavity that is directly accessible 
from the surface of the enzyme (Gillmor et al. 1997). 
 
Figure 1 Crystal structure of 15-LOX-1. The N-terminal domain consists of 
eight anti-parallel β-barrel sheets (indicated in yellow on the left). The 
catalytic C-terminal domain is made up of 18 helices (indicated in red) and a 
small β-sheet sub-domain (indicated in yellow on the right). The non-heme 
iron is located in the centre of the helical formation (indicated in purple). 15-
LOX-1 is localised in the cytoplasm as shown by its position below the blue 
dotted line (representing the cytoplasmic side). Adapted from (Lomize et al. 
2006). 
 
LOXs are catalytically inactive and are activated by hydroperoxy fatty 
acids, causing the oxidation of the non-heme iron to its ferric form. Upon 





metabolites with different biological activities. Ester lipids such as 
phospholipids and cholesterol esters, and complex lipid-protein assemblies 
such as biomembranes and lipoproteins are 15-LOX-1 substrates as well 
(Kuhn et al. 2002). Metabolism of linoleic acid generates 13S-HPODE which 
is rapidly reduced to 13S-HODE (Auerbach et al. 1992). Metabolism of EPA 
produces 15S-hydroperoxyeicosapentaenoic acid (15S-HPEPE) before it is 
reduced to 15S-hydroxyeicosapentaenoic acid (15S-HEPE) (Vang and Ziboh 
2005). 15S-HEPE can be further converted to lipoxins A5 and B5 in leukocytes 
(Lam et al. 1987). Arachidonic acid is released from membrane phospholipids 
by cPLA2 (Ong et al. 1999), which is acted on by 15-LOX-1 leading to the 
generation of 15S-HPETE as a major product and 12S-HPETE as a minor 
product, which are then rapidly converted to 15S-HETE and 12S-HETE, 
respectively (Ivanov et al. 2015). While these products have their own 
functional roles, they may be further metabolised. For instance, 5-LOX acts on 
15S-HETE to form an epoxy intermediate which is then hydrolysed to lipoxin 
A4 (LXA4) or lipoxin B4 (LXB4) (Serhan et al. 1984) (Figure 2). 15-LOX-1 is 
also able to metabolise DHA. DHA is the most abundant fatty acid in the brain 
and is richly present in neural membranes (Piomelli et al. 2007). Calcium-
independent phospholipase A2 (iPLA2), a member of the phospholipase A2 
family, releases DHA from membrane glycerophospholipids (Green et al. 
2008), which seems to occur upon cholinergic and serotonergic receptor 
activation and during ischaemia (Green et al. 2008; Bazan et al. 2011). 15-
LOX-1 dioxygenates DHA to produce 17S-hydroperoxydocosahexaenoic acid 
(17S-HpDHA) which is converted to 17S-hydroxydocosahexaenoic acid (17S-





via 5-LOX, to docosanoids, DHA-derived metabolites which include resolvins 
and protectins (Figure 2). In the absence of 5-LOX, protectin D1 (PD1) is 
formed from 17-HpDHA (Barden et al. 2014). Resolvins and protectins 
derived from DHA are specifically referred to as resolvin D1 (RvD1) and 
(neuro)protectin D1. Similar to arachidonic acid-derived lipoxins, these 




















Figure 2 Illustration of pathways mediated by 15-LOX-1. LXA4, lipoxin 
A4; LXB4: lipoxin B4; RvD1: resolvin D1; NPD1, neuroprotectin D1; MaR1, 
maresin 1; ALX: lipoxin receptor; GPR32: G protein-coupled receptor 32. 
Adapted from (Basil and Levy 2016). 
 
2.3.2.2  Biological roles of 15-LOX-1 and its metabolites 
Due to the ability of 15-LOX-1 to modify ester lipid-containing 
polyenoic fatty acids incorporated into complex lipid-protein assemblies such 
as biomembranes and lipoproteins, thus modifying their structural and 
functional parameters, it plays a role in cellular organelle restructuring. 





terminal cell differentiation (Il Lee et al. 2011). One of the earliest 
demonstrations of this role is erythrocyte maturation. Under normal 
circumstances, healthy erythrocytes do not express high levels of 15-LOX-1; 
however, during anaemia, immature reticulocytes upregulate their expression 
of 15-LOX-1 causing mitochondrial degradation for subsequent maturation 
(Vijayvergiya et al. 2004). 15-LOX-1 is also indicated in adipocyte 
differentiation, since inhibition of this enzyme has been shown to prevent the 
maturation of 3T3-L1 cells (Madsen et al. 2003). The peroxisome proliferation 
activating receptor gamma (PPARγ) was suggested as the mediator of this 
effect of 15-LOX-1, and both 13-HODE and 15S-HETE can co-activate 
PPARγ (Huang et al. 1999; Shappell et al. 2001), supporting the physiological 
role of 15-LOX-1 in adipocyte maturation. 15-LOX-1 also contributes to the 
terminal differentiation of cells in the eye lenses (van Leyen et al. 1998) and 
human nasal and bronchial epithelia (Hill et al. 1998; Kim et al. 2005). 
 
2.3.2.3  15-LOX-1 in the brain 
Products of cPLA2 and 15-LOX metabolism of arachidonic acid have 
been indicated in brain development and synaptic signalling. 12S-HPETE, 
12S-HETE and 15S-HETE are important signalling mediators that have 
demonstrated ability to provide guidance cues for growth cones in nervous 
system development (de La Houssaye et al. 1999; Ross et al. 2000). These 
metabolites are also thought to be secondary messengers and are involved in 
paracrine signalling in glia and neurons (Phillis et al. 2006). DHA and its 
derived docosanoids play important roles in synaptic transmission (Tanaka et 





inflammatory pain behaviours in mice by normalising the spinal synaptic 
plasticity involved in pain hypersensitivity (Xu et al. 2010). 15-LOX-1 is also 
possibly involved in learning and memory. A previous study demonstrated 
that knockdown of the iPLA2 enzyme in the rat prefrontal cortex prevented the 
induction of hippocampo-prefrontal cortical long-term potentiation (LTP) 
(Shalini et al. 2014). Preliminary results from our lab suggests that 
downstream of iPLA2, 15-LOX-1 is also involved in learning and memory, 
given that intracortical injection of a 15-LOX-1 inhibitor PD146176 and 
antisense oligonucleotide into the rat prefrontal cortex led to poorer 
performance on memory tasks and lack of induction of hippocampo-prefrontal 
cortical LTP (Shalini et al., unpublished data). This was associated with 
reduced levels of RvD1 in the prefrontal cortex after 15-LOX-1 inhibition 
(Shalini et al., unpublished data). Given that iPLA2 releases DHA from 
membrane phospholipids and DHA deficiency in the brain leads to poorer 
memory and learning deficits (Salem et al. 2001), 15-LOX-1 and its 
docosanoids may be imperative for induction of LTP and cognitive functions. 
 
2.4 Pathological roles of 15-LOX-1 
2.4.1 15-LOX-1 in carcinogenesis 
 15-LOX-1 is involved in terminal differentiation of cells (Kuhn et al. 
2002). A crucial mechanism of tumourigenesis is the loss of the potential of 
cells to differentiate (Jimenez and Yunis 1987). In many cancers, cells lose 
their ability to terminally differentiate and this is associated with reduced 15-
LOX-1 expression (Moussalli et al. 2011), indicating an anti-tumourigenic 





LOX-1 and its metabolites in the inhibition of the development, progression 
and metastasis of cancer. The anti-tumourigenic property of 15-LOX-1 is 
linked to its activation of PPARγ which, in cancer cells, inhibits nuclear factor 
kappa B (NFκB) (Cimen et al. 2011), suppresses growth and induces apoptosis 
(Elrod and Sun 2008). Reduced expression of 15-LOX-1 and the subsequent 
decrease in 15S-HETE and 13S-HODE has been implicated in the 
development of lung cancer via a reduction in PPARγ activation (Yuan et al. 
2010). DHA metabolites 17S-HpDHA and 17S-HDHA, from 15-LOX-1 
metabolism, were also reported to inhibit the proliferation and survival of 
prostate cancer cells via activation of PPARγ (O'Flaherty et al. 2012). 
 
2.4.2 15-LOX-1 in inflammation 
Due to the diverse pathways that LOXs participate in, it is possible for 
products with either pro- and anti-inflammatory properties to be formed in 
each step of the catalytic pathway. Literature evidence thus far indicates an 
important role of LOXs and their products in the regulation of many 
physiological processes, placing them at the centre of many disease models. 
15-LOX-1, in particular, takes part in pathways that produces pro- and anti-
inflammatory metabolites. A key factor that determines the role of 15-LOX-1 
during inflammation seems to be the spectrum of available substrates, which 
depends on the type of cell and tissue (Uderhardt and Kronke 2012).  
Traditionally, the products of 15-LOX-1 metabolism were classified as 
pro-inflammatory. 15S-HPETE was reported to cause inflammation in the 
rabbit skin (Higgs et al. 1981) and 15S-HETE is a potent inflammatory 





13S-HODE and 15-HPETE induce apoptosis, reduce cellular viability, 
increase intracellular calcium, and cause DNA fragmentation in T cell lines 
(Sandstrom et al. 1995). In rabbit pulmonary arteries, long periods of hypoxia 
were found to induce 15-LOX-1 expression and exacerbate arterial 
constriction (Zhu et al. 2003). A pathophysiological role of 15-LOX-1 has also 
been established in allergic diseases such as asthma (Bradding et al. 1995; Chu 
et al. 2002), where both 15-LOX-1 and 15S-HETE have been discovered to be 
present in levels higher than normal (Profita et al. 2000). 
However, the same 15-LOX-1 products that were classified as pro-
inflammatory may be anti-inflammatory and mediate resolution of 
inflammation (Herlin et al. 1990; Munger et al. 1999; Montero and Badr 2000). 
For example, 15S-HETE antagonises the chemotactic action and synthesis of 
leukotriene B4 in rats (Levy et al. 2005). Overexpression of 15-LOX-1 is 
known to inhibit inflammation in animal models (Serhan et al. 2003). 15-
LOX-1 activity has been shown to inhibit NFκB by activating PPARγ (Cimen 
et al. 2011) through 15S-HETE and 13-HODE. Arachidonic acid-derived 15S-
HETE may be further modified, via 5-LOX, to generate LXA4 and LXB4 
which possess anti-inflammatory and pro-resolving properties. Lipoxins are 
lipid mediators involved in the resolution phase of inflammation. As potent 
regulators of both leukocytes and cytokine production, they counteract 
endogenous pro-inflammatory mediators such as leukotrienes and cytokines 
such as tumour necrosis factor (TNF-α) and IL-6, resulting in inhibition of 
leukocyte-dependent inflammation (Serhan 1997). Lipoxin analogues have 
been shown to be topically active and anti-inflammatory when applied to 





involved in resolution of inflammatory and neuropathic pain. Administration 
of LXA4 or LXB4 were noted to reduce carrageenan-induced inflammatory 
hind paw thermal hyperalgesia, and this effect was associated with 
extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase 
inhibition (Svensson et al. 2007). LXA4 injection was also found to reduce 
mechanical allodynia and thermal hyperalgesia by inhibiting NFκB and pro-
inflammatory cytokine expression (Sun et al. 2012). PUFAs such as DHA 
have been observed to be beneficial for inflammatory disease, and it was only 
recently that their anti-inflammatory mechanisms of action were understood. 
Molecules derived from omega-3 PUFAs were identified as actively taking 
part in the resolution process (Kohli and Levy 2009). Furthermore, resolvins 
and neuroprotectins can modulate the effects of pro-inflammatory eicosanoids 
derived from arachidonic acid (Hong et al. 2003), modulate leukocyte 
trafficking and downregulate cytokine expression (Marcheselli et al. 2003). 
RvD1 was also shown to be pro-resolving and anti-inflammatory by 
modifying the balance of production of pro- and anti-inflammatory cytokines 
(Hsiao et al. 2013; Erdinest et al. 2014). 
 
2.4.3 15-LOX-1 in neuroinflammation and neurodegeneration 
 Given the ability of 15-LOX-1 to generate a host of pro- and anti-
inflammatory mediators, its activity during neuroinflammation can be 
described as a double-edged sword. The brain is believed to be highly 
susceptible to oxidative stress as it is abundant in PUFAs that are vulnerable to 
lipid peroxidation (Adibhatla and Hatcher 2007). LOXs and their products 





diseases such as stroke and AD (Pratico et al. 2004; Chu et al. 2012) due to 
their damaging lipid-oxidising properties, which generate metabolites such as 
12S- and 15S-HPETE, and 12S- and 15S-HETE (Loscalzo 2008). 15-LOX-1 
is indicated in axon degeneration caused by neuronal injury by activating 
caspase and increasing mitochondrial permeability, causing neuronal apoptosis 
(Rudhard et al. 2015). Increased 15-LOX-1 protein in neurons and a large 
increase in metabolic products generated from 15-LOX-1 activity were 
observed in models of stroke and ischaemia-reperfusion (Moskowitz et al. 
1984; van Leyen et al. 2006). Higher levels of 15-LOX-1, together with 
marked increases in 12S- and 15S-HETE, were detected in the frontal and 
temporal regions of AD brains, compared to non-diseased brains (Pratico et al. 
2004) and knockout of the 15-LOX-1 gene reduced cellular oxidative stress 
after exposure to hydrogen peroxide and Aβ in vitro. Increased levels of 12S- 
and 15S-HETE were also observed in the cerebrospinal fluid of individuals 
with mild cognitive impairment and AD, which was associated with lipid 
peroxidation and tau protein levels (Yao et al. 2005). 15-LOX-1 was 
discovered to modulate tau metabolism via the cdk5 kinase pathway, causing 
increased levels of tau when 15-LOX-1 is overexpressed (Giannopoulos et al. 
2013). Under oxidative stress, the role of 15-LOX-1 may be amplified in light 
of its lipid peroxidation activities. It was demonstrated that 15-LOX-1 adds on 
to oxidative stress by damaging mitochondria, resulting in release of 
cytochrome c and ROS generation (Pallast et al. 2009). 
On the other hand, certain metabolites of the 15-LOX-1 pathway 
possess anti-inflammatory and neuroprotective properties, and contribute to 





ischaemia, generating increased 12S-HETE and 15S-HETE which leads to 
PPARγ activation and subsequent neuroprotection (Han et al. 2015; Sun et al. 
2015). LXA4 protects neurons against cerebral ischaemia (Wu et al. 2010), 
traumatic brain injury (Luo et al. 2013) and Aβ toxicity (Wu et al. 2011) by 
modulating inflammation, inhibiting inflammatory pain processing (Svensson 
et al. 2007), and is also involved in neurodegenerative diseases (Wang et al. 
2015). Resolvins and protectins, which are pro-resolving mediators (Serhan et 
al. 2004), are involved in the resolution of neuroinflammation and pain (Xu et 
al. 2010) They enhance the clearance of apoptotic cells and debris from 
inflamed brain tissue (Farooqui 2011) Administration of RvD1 was observed 
to reverse synaptic dysfunction and cognitive decline associated with surgery 
(Terrando et al. 2013). Lower levels of neuroprotectin D1 in AD brains, which 
was attributed to a decreased expression of 15-LOX-1 coupled with an 
increased expression of cPLA2, therefore neuroprotectin D1 is necessary for 
neuronal survival by inducing neuroprotective gene expression which 
attenuates Aβ-mediated neurotoxicity (Lukiw et al. 2005). Neuroprotectin D1 
also protects against neuronal apoptosis caused by oxidative stress (Bazan 
2005; Bazan 2006) and inhibits DNA damage caused by apoptosis during 







 A genome is the complete set of genetic information stored in the form 
of DNA in an organism. In the cell nucleus, DNA is packaged into a highly 
compact structure known as chromatin, which comprises an assembly of 
nucleosomes (Kornberg 1974). Nucleosomes are the result of the interaction 
between DNA and histone proteins. A 147bp DNA segment wraps around a 
histone octamer core, formed by two H3-H4 histone dimers bound together as 
a stable tetramer and flanked by two separate H2A-H2B dimers (Luger et al. 
1997). Epigenetics is a process whereby gene activity and expression is altered 
without any changes to the DNA sequence, which can be transmitted to 
daughter cells. This results in cells with identical DNA differentiating into 
different cell types with different phenotypes (Ling and Groop 2009). 
Epigenetic processes can be induced by a variety of environmental and 
lifestyle factors including diet, exercise and exposure to environmental 
pollutants (Alegria-Torres et al. 2011), and can be induced by ageing as well 
(Burzynski 2005). The organisation of chromatin structure and regulation of 
gene transcription is driven by two factors: covalent modifications of DNA 
and post-translational modifications of histone proteins. Covalent 
modifications of DNA include methylation of the nucleobases cytosine, 
adenine and guanine (Hotchkiss 1948), whereas post-translational 
modifications of histone proteins involve modifications of specific amino acid 
residues on the histone tails (Kouzarides 2007). Epigenetic factors include 
DNA methylations (Lim and Maher 2010), histone modifications (Bannister 






3.1 Histone modifications 
Histone modifications are an extensive component of epigenetic 
processes. These modifications include histone acetylation, methylation, 
phosphorylation and ubiquitination (Bannister and Kouzarides 2011) and lead 
to changes in chromatin structure. The amino N-terminal tails of histones can 
extend out of their nucleosomes and interact with adjacent nucleosomes; 
therefore, alterations of these tails can influence inter-nucleosomal interactions 
and affect chromatin structure (Bannister and Kouzarides 2011). These tails 
are rich in basic lysine residues (K) that give rise to an overall positive charge 
which contrasts the negative charge of DNA (Margueron and Reinberg 2010). 
These opposing charges render chromatin tightly packed and present a barrier 
to the machinery that either transcribes, replicates, or repairs DNA. 
Modifications of histones serve to remove this barrier by influencing the 
compactness of chromatin. 
To date, the best characterised modifications are acetylations and 
methylations of lysine residues on histones H3 and H4. Addition of acetyl 
groups to lysine residues remove their positive charges, decreasing the affinity 
between DNA and histones, thereby resulting in an open chromatin structure 
which is accessible for gene transcription (Hong et al. 1993; Lee et al. 1993; 
Vettese-Dadey et al. 1996). On the contrary, deacetylation involves the 
removal of acetyl groups from lysine residues. The restoration of positive 
charges on these lysine residues permits DNA to wrap tightly around the 
histone cores, promoting condensed chromatin and inhibiting gene 
transcription. These acetylations and deacetylations are catalysed by enzymes 





(HDACs), respectively. HDACs and HATs do not bind to DNA directly; 
instead, they interact with DNA together with co-repressors and co-activators 
in multi-protein complexes (Marmorstein 2001; Sengupta and Seto 2004) 
(Figure 3). The amino acid residue most commonly acetylated is lysine and 
those that are well-characterised include histone 3 lysine 9 (H3K9), 14 
(H3K14) and 27 (H3K27), and histone 4 lysine 5 (H3K5), 8 (H3K8), 12 
(H3K12) and 16 (H3K16) (Bjerling et al. 2002). 
Figure 3 Illustration of HDAC and HAT activities on chromatin 
transcription. Ac, acetyl residue; HAT, histone acetyltransferase; HDAC, 
histone deacetylase. Adapted from (de Ruijter et al. 2003). 
 
On the other hand, histone methylation involves addition of methyl 
groups to amino acid residues on histone tails by enzymes known as histone 
methyltransferases (HMTs). Unlike histone acetylation, methyl groups do not 
alter the charges on amino acid residues, but increases their basicity and 
hydrophobicity (Rice and Allis 2001). However, gene transcription is either 
promoted or inhibited depending on which residues are methylated and the 





instance, methylation of H3K9 and H3K27 is associated with transcriptional 
silencing in euchromatin (Hwang et al. 2001). However, di- and tri-
methylation of H3K4 is associated with active transcription (Schneider et al. 
2004). 
 
3.1.1 Histone acetyltransferases (HATs) 
 HATs are enzymes that transfer an acetyl group from acetyl CoA to 
amino acid residues on histone tails (Roth et al. 2001). HATs are classified 
into type A or type B HAT depending on their cellular localisation. Type A 
HATs are located in the nucleus and are the main enzymes responsible for 
gene transcription (Roth et al. 2001). There exists many families of type A 
HATs and they are categorised by their catalytic domains. The GCN5-related 
N-acetyltransferase (GNAT) family is characterised as having a unique C 
motif (Sterner and Berger 2000) and comprises GCN5, PCAF, Elp3, Hat1a, 
Hpa2 and Nut1a (Lee and Workman 2007). The MYST HAT family is named 
after Morf, Ybf2 (Sas3), Sas2 and Tip60. These members possess a particular 
acetyltransferase homology region (part of motif A of the GNAT family) 
(Sterner and Berger 2000). The p300/CBP HAT family comprises of p300 and 
CBP (CREB-binding protein), which are transcriptional co-activator 
homologues that are involved in many cellular processes (Shiama 1997; 
Giordano and Avantaggiati 1999). Besides these three well-characterised 
families, nuclear receptor coactivators and TBP-Associated Factor TAFII250 
are examples of co-activators and transcription factors that possess HAT 
activities as well (Sterner and Berger 2000). On the other hand, type B HATs 





Type B HAT members have roles in DNA repair and histone deposition 
(Blanco-Garcia et al. 2009). Many of these HATs have various roles in 
cellular homeostasis such as cell growth and differentiation (Chan and La 
Thangue 2001; Sartorelli and Puri 2001). 
 HAT inhibitors are widely used to study histone acetylation and gene 
regulation. Synthetic HAT inhibitors include butyrolactone-3 (MB-3) which 
inhibits GCN5 HAT, NU9056, which inhibits Tip60 HAT, and C646, which 
inhibits p300/CBP HAT. Besides inhibition of HAT activity, HAT inhibitors 
can also inhibit proliferation, sensitise cancer cells to radiation (Sun et al. 2006) 
and induce apoptosis in cancer cell lines (Xu et al. 2014). 
 
Table 3.1 HAT inhibitors and affected histone residues 
HAT inhibitors Selectivity Histone 
residues 
Reference 
MB-3, MC1626 GCN5 H3K9, H3K14, 
H3K18, H3K23, 
H3K27, H3K36 
(Biel et al. 2004; 









(Ogryzko et al. 1996; 
Das et al. 2009; 
Bowers et al. 2010; 
Valor et al. 2013; 
Yang et al. 2013; 













H4K16 Ghizzoni et al. 2012; 
Gao et al. 2014) 
 
3.1.2 Histone deacetylases (HDACs) 
 HDACs are enzymes that catalyse the removal of acetyl groups from 
amino acid residues on histone tails, thereby promoting a more compact 
chromatin structure. The classical HDAC family includes class I and class II 
HDACs (de Ruijter et al. 2003). Class I HDACs include HDACs 1, 2, 3 and 8 
(Delcuve et al. 2012). Class II HDACs are further classified into class IIa and 
IIb, where class IIa HDACs comprise HDACs 4, 5, 7 and 9 whereas class IIb 
HDACs consist of HDACs 6 and 10 (Yang and Gregoire 2005). These 
HDACs require a zinc ion (Zn2+) as a cofactor for activity (Lombardi et al. 
2011). Class I HDACs have a high level of homology to the yeast 
transcriptional regulator RPD3 (de Ruijter et al. 2003) and class II HDACs 
possess similar domains to a deacetylase found in yeast known as HDA1 
(Bjerling et al. 2002). The class III HDACs are known as sirtuins. Sirtuins are 
structurally distinct from class I and II HDACs and are homologues of the 
NAD+-dependent yeast HDAC silent information regulator (Sir2) (North and 
Verdin 2004). Class IV HDAC has only one member thus far, HDAC11, a 
newly discovered HDAC (Gao et al. 2002) which is homologous with class I 
and II HDACs (Ropero and Esteller 2007). 
 HDAC inhibitors are compounds that inhibit HDAC activity, 
preventing the removal of acetyl groups from amino acid residues, thereby 
allowing chromatin to remain open and accessible to transcription factors. 





Trichostatin A (TSA) and sodium butyrate (NaBT) are examples of general 
HDAC inhibitors that target class I and II HDACs, but not class III HDACs 
(Candido et al. 1978; Davie 2003; Ropero and Esteller 2007). Tubacin is a 
HDAC6 inhibitor that causes hyperacetylation of microtubules (Zilberman et 
al. 2009). MS-275 is a specific HDAC inhibitor that inhibits HDAC1, HDAC2 
and HDAC3 (Hess-Stumpp et al. 2007), whereas depsipeptide is a HDAC1 
and HDAC2 inhibitor (Kim and Bae 2011). Almost all HDAC inhibitors can 
induce cell-cycle arrest, cellular differentiation or apoptosis, and possess anti-
tumour activities (Weidle and Grossmann 2000; Marks et al. 2001). 
 
Table 3.2 HDAC inhibitors and affected histone residues 
HDAC 
inhibitors 
Selectivity Histone residues  Reference 
Trichostatin 
A (TSA) 
HDAC 1, 2, 3, 
8 (Class I); 
HDAC 4, 5, 7, 




(Zhong et al. 2003; 
Wu et al. 2012; Seo 




HDAC 1, 2, 3, 
8 (Class I); 
HDAC 4, 5, 7, 
9 (Class IIa) 
H3K9, H3K14, 
H4K8 
(Karmodiya et al. 
2012; Terova et al. 
2016) 




(Covington et al. 
2009; Huang et al. 
2011; Bahari-Javan 
et al. 2012) 





(Class I) H4K8, H4K12 Klisovic et al. 2003) 
Tubacin HDAC 6 
(Class IIb) 
NIL (Zilberman et al. 
2009) 
 
3.1.3 Histone methyltransferases (HMTs) 
Histone methyltransferases (HMTs) are a class of enzymes that 
transfer methyl groups to specific amino acid residues, namely lysine and 
arginine, on the tails of histones H3 and H4. Different degrees of methylation 
can occur on these residues. For instance, lysines can be mono-, di-, or tri-
methylated, whereas arginines can be mono- or di-methylated. The most 
commonly studied methylation sites include histone H3 lysine 4 (H3K4), 
H3K9, H3K27 and H4K20, among others (Greer and Shi 2012). Lysine-
specific HMTs are classified into SET domain-containing HMTs and non-SET 
domain-containing HMTs. Another family of HMTs is the DOT1 set of HMTs, 
whose members are structurally unrelated to SET-domain proteins and 
catalyse the methylation of K79 in the globular core of histone 3 (Feng et al. 
2002; Ng et al. 2002). These HMTs require S-adenosylmethionine as a co-
substrate for methylation (Bissinger et al. 2010). Histone methylation is 
associated with activation of neural pathways that are crucial for long-term 
memory formation and learning (Kramer 2013).  
5'-deoxy-5'-methylthioadenosine (MTA) is an example of a general 
lysine-specific HMT inhibitor. MTA inhibits SET1 methyltransferases, which 







3.2 Epigenetics and neuroinflammation 
There is substantial evidence that inflammatory events may mediate 
changes in the epigenome, where persistence of inflammation can induce 
phenotypical and epigenetic changes in immune cells and lead to eventual 
tissue destruction. Inflammation can cause increased acetylation of histones at 
the promoters of pro-inflammatory cytokines, leading to subsequent 
transcriptional activation (Villagra et al. 2010). Glial cells such as astrocytes 
(Farina et al. 2007) and microglia (Aguzzi et al. 2013) are highly involved in 
CNS inflammation and studies have shown that epigenetic modifications 
affect these glial cells during inflammation. Activated microglia decrease 
histone H3 acetylation and levels of the transcription factor nuclear factor-
erythroid 2-related factor 2 (Nrf2) in astrocytes which is responsible for 
antioxidant defence (Correa et al. 2011). Global DNA hypomethylation has 
been reported in a population of activated microglia in traumatic brain injury 
(Zhang et al. 2007). Ischaemia generally leads to transcriptional repression 
given the decrease in acetylation of histones H3 and H4 (Ren et al. 2004; Kim 
et al. 2007; Wang et al. 2011; Xuan et al. 2012).  
HDAC inhibitors have been shown to be anti-inflammatory and 
neuroprotective. For instance, treatment with HDAC inhibitors led to 
inactivation of microglia and improved neurological outcomes in brain injury 
and stroke models (Ren et al. 2004; Kim et al. 2007; Zhang et al. 2008; Shein 
et al. 2009; Xuan et al. 2012). HDAC inhibitors can also prevent astrocyte 
dysfunction caused by activated microglia (Correa et al. 2011) and promote 
release of neurotrophic factors from astrocytes (Chen et al. 2012). HDAC 





attenuate inflammation and protect against demyelination and neuronal loss 
(Camelo et al. 2005). These findings suggest that epigenetic events and 
inflammation are linked and HDAC inhibitors have anti-inflammatory and 
neuroprotective potential in neuroinflammation. 
 
3.3 Epigenetics and neurodegenerative diseases 
Epigenetic processes play essential roles in embryonic development, 
cell differentiation and maintenance of the cellular identity. Exposure to 
environmental factors over a person’s lifespan influences epigenetic processes 
in the genome, regulating the expression of various genes. The study of 
epigenetic processes on CNS development, cognition, neurological and 
neurodegenerative pathology allows a better understanding between epigenetic 
markers and neuronal function (Sweatt 2013). Alterations in the genome due 
to epigenetic changes affect neuronal function and physiology (Landgrave-
Gomez et al. 2015). Many lines of evidence have shown methylation and other 
epigenetic mechanisms to be associated with conditions of ageing and 
neurodegenerative diseases (Mastroeni et al. 2010; Hernandez et al. 2011; 
Chouliaras et al. 2013). Global DNA hypermethylation (Rao et al. 2012), tri-
methylation of histone H3 (Chouliaras et al. 2010) and increased HDAC6 
(Zhang et al. 2013) have been observed in AD. Epigenetic mechanisms are 
highly involved in formation and maintenance of memory (Zovkic et al. 2013). 
For instance, overexpression of HDAC2 in neurons can decrease dendritic 
spine density, number of synapses, synaptic plasticity, and inhibit memory 
formation in mice (Guan et al. 2009). Memory loss associated with ageing and 





tails (Zhang et al. 2012), increased levels of HDACs (Ding et al. 2008; Graff 
et al. 2012) and reduced methylation levels (Mastroeni et al. 2010; Chouliaras 
et al. 2013). In PD, reduced methylation levels of the α-synuclein gene 
(Jowaed et al. 2010; Matsumoto et al. 2010) and increased HDAC6 in Lewy 
bodies (Kawaguchi et al. 2003) were observed in the brains of PD patients. 
Treatment with HDAC inhibitors has shown to reverse memory loss (Kilgore 
et al. 2010) and improve learning and memory (Fischer et al. 2007; 
Govindarajan et al. 2011) in AD, and reduce neurotoxicity associated with α-
synuclein in PD (Kontopoulos et al. 2006). These findings demonstrate the 
crucial role of epigenetic processes in physiological neuronal functions as well 





4.0 Formyl-peptide receptors 
 The formyl-peptide receptors (FPRs) are a family of seven 
transmembrane G protein-coupled receptors (GPCRs) which were originally 
identified on the surface of neutrophils and macrophages. The gene encoding 
FPR was first identified in humans, and is known as FPR1. The FPR gene is 
located on chromosome 19 and spans 6 kb (Perez et al. 1992). Subsequently, 
two other structural homologues, namely FPR2 (also known as formyl-peptide 
receptor-like 1/FPRL1), and the putative receptor FPR3 (also known as 
formyl-peptide receptor-like 2/FPRL2), were cloned and characterised. All 
three homologues are clustered on chromosome 19 (Le et al. 2001b). The three 
human FPRs, FPR1, FPR2, and FPR3 share significant sequence homology 
(Ye et al. 2009). Human FPR2 shares 69% amino acid sequence similarity 
with human FPR1 (Ye et al. 1992), whereas the human FPR3 gene encodes a 
putative protein with 56% amino acid sequence identity to human FPR1 and 
83% to human FPR2 (Bao et al. 1992; Murphy et al. 1992). These GPCRs are 
coupled to G proteins of the inhibitory type (Gierschik et al. 1989), therefore 
their activation leads to transient calcium ion mobilisation, ERK 
phosphorylation (He et al. 2003), and cell motility (Babbin et al. 2006). While 
the three isoforms have high sequence homology, they possess very different 
pharmacological properties due to the different ligands they respond to 
(Chiang et al. 2006). 
 FPRs are originally identified as a family of anti-microbial receptors. 
In bacterial infections, N-formyl oligopeptides, such as the tripeptide N-
formyl-methionyl-leucyl-phenylalanine (fMLP), released by bacterial cells 





inducing chemotaxis, granule enzyme secretion, calcium ion mobilisation, and 
respiratory burst (Le et al. 2002). As N-formyl oligopeptides are only present 
in bacterial (Marasco et al. 1984) and mitochondrial proteins (Carp 1982), it 
has been widely thought that these receptors evolved to mediate phagocyte 
chemotaxis to sites of bacterial invasion or tissue damage (Le et al. 2002). 
Mice without functional FPR1 are more susceptible to bacterial infections 
(Gao et al. 1999), and treatment of FPR1- and FPR2-expressing primary 
murine microglial cells with lipopolysaccharide (LPS) results in an FPR2-
mediated activation (Cui et al. 2002a), suggesting that FPR1 and FPR2 are 
crucial for antimicrobial host defence against bacterial endotoxins. 
 
4.1 Formyl-peptide receptor 2 (FPR2) 
 The formyl-peptide receptor 2 (FPR2) is also known as FPRL1 due to 
its high cDNA and amino acid sequence similarity to FPR1. In the mouse, six 
isoforms of FPR were cloned and named Fpr-rs1 through Fpr-rs5, and found 
on chromosome 17 (Gao et al. 1998). Fpr-rs1 and Fpr-rs2 have 75% 
nucleotide identity to human FPR2 (Gao et al. 1998; Hartt et al. 1999). 
Although FPR1 and FPR2 have high sequence similarity, FPR2 is slightly 
different in terms of its characteristics and functions. For instance, while FPR1 
has the highest affinity for N-formyl oligopeptides, FPR2 is only activated by 
high concentrations of N-formyl oligopeptides in the micromolar range in 
vitro (Prossnitz and Ye 1997) and can only elicit calcium ion mobilisation but 
not chemotaxis (Bao et al. 1992; Ye et al. 1992), making it a low-affinity 
receptor for these bacterial peptides. Human FPR2 is present at high levels on 





killer (NK) cells (Spurr et al. 2011). Human FPR2 is able to detect bacterial 
endotoxins such as peptides released by the highly pathogenic Staphylococcus 
aureus, launching pro-inflammatory neutrophil responses as part of the innate 
host defence (Kretschmer et al. 2010). Additionally, FPR2-knockout mice 
exhibit pronounced inflammatory responses to ischaemia-reperfusion injury, 
demonstrating the protective role of FPR2 in inflammation (Dufton et al. 
2010). 
 
4.1.1 Multi-ligand nature of FPR2 
FPR2 is the first receptor demonstrated to recognise and bind a large 
and diverse group of ligands of both lipid and protein origin (Fiore et al. 1994; 
Le et al. 2001b; Migeotte et al. 2006) that evoke opposing biological responses, 
particularly in host-modulated immune response (Chiang et al. 2006) (Figure 
4). Activation of FPR2 by its ligands triggers a series of G protein-mediated 
signalling cascades leading to cell adhesion, migration, calcium mobilisation, 
release of reactive oxygen intermediates and production of pro- and anti-
inflammatory cytokines (Le et al. 2000). Of these ligands, LXA4 binds with 
high affinity to FPR2, thus FPR2 is commonly known as FPR2/ALX (Fiore et 
al. 1994). Besides being a ligand of FPR2, LXA4 can enhance FPR2 promoter 
activity and mRNA expression in vitro (Simiele et al. 2012). LXA4 is a potent 
anti-inflammatory and pro-resolving lipid mediator whose effects are mediated 
by FPR2 activation. LXA4 inhibits production of pro-inflammatory cytokines 
and enhances the clearance activities of macrophages via the p38 MAP kinase 
(MAPK) pathway (Wu et al. 2014). It can also inhibit neutrophil responses 





(Kure et al. 2010). Another important lipid ligand of FPR2 is RvD1. Growing 
evidence suggests that RvD1 acts via FPR2 (Krishnamoorthy et al. 2010; 
Krishnamoorthy et al. 2012) to regulate short endogenous RNAs known as 
miRNAs that are important regulators for resolution of inflammation (Bartel 
2009; Recchiuti et al. 2011; Recchiuti 2013). Evidence for FPR2 mediating 
the effects of RvD1 was shown in a study where RvD1 reduced peritoneal 
leukocyte infiltration in wild-type mice and this effect was abolished in FPR2-
deficient mice (Norling et al. 2012). Stimulation of human monocytes with 
RvD1 enhanced phagocytosis, a response which improved when these cells 
overexpressed FPR2 (Krishnamoorthy et al. 2010). Furthermore, RvD1 is able 
to promote the activation of LXA4 biosynthesis during inflammation (Norling 
et al. 2016). These findings suggest that the anti-inflammatory and pro-
resolving effects of LXA4 and RvD1 can be mediated through FPR2. 15-
LOX-1 is, therefore, interlinked with FPR2 as it produces LXA4 and RvD1 
from PUFAs which are agonists of FPR2. 
Other ligands of FPR2 include annexin I (lipocortin I) (Walther et al. 
2000) and humanin (Ying et al. 2004). Annexin I is an endogenous 
glucocorticoid-regulated protein highly expressed in neutrophils (Le et al. 
2002). Annexin I has been shown to be anti-inflammatory by preventing 
neutrophil trafficking (Hayhoe et al. 2006), activating neutrophil apoptosis 
(Vago et al. 2012), promoting monocyte recruitment (McArthur et al. 2015) 
and clearance of apoptotic leukocytes by macrophages (Arur et al. 2003). 
Humanin, a mitochondrial-derived peptide (Hashimoto et al. 2001), is a 
protective mediator against oxidative stress (Bachar et al. 2010) and is best 





receptor for these ligands, FPR2 plays a crucial role in mediating the 
resolution of inflammation. 
 
Figure 4 Illustration of the multi-ligand nature of FPR2/ALX. LXA4, 
lipoxin A4; ATL, aspirin-triggered lipoxin A4; ATLa, aspirin-triggered 
lipoxin stable analogue; NF-κB, nuclear factor kappa B; PMN, 
polymorphonuclear neutrophil. Adapted from (Chiang et al. 2006). 
 
4.1.2 Role of FPR2 in neuroinflammation and neurodegenerative 
diseases 
 The various ligands of FPR2 have expanded its role and involvement 
in complex diseases. The brain is abundant in PUFAs which are precursors of 
LXA4 and RvD1. In neuroinflammation, these lipid mediators are imperative 
in resolving inflammation and maintaining brain homeostasis. In the CNS, 
FPR2 has been found present in immune cells, neural stem cells and resident 
cells (Maddox et al. 1997; Wada et al. 2006), making them potential targets 
for LXA4 and RvD1 in the brain. Various studies have reported the anti-
inflammatory and neuroprotective effects of LXA4 in brain injury (Luo et al. 
2013; Guo et al. 2016) and ischaemia (Ye et al. 2010) through its binding to 
FPR2, leading to reduced inflammatory responses such as decreased 





outcomes. Although very few studies have described the anti-inflammatory 
role of RvD1 in the CNS, its effects may be similar to those observed in the 
periphery such as inhibition of leukocyte chemotaxis (Claria et al. 2012), 
reduced pro-inflammatory cytokine production (Schwab et al. 2007; Tian et al. 
2009) and enhanced phagocytosis of apoptotic cells (Krishnamoorthy et al. 
2010; Chiang et al. 2012).  
 FPR2 is a pathophysiologically-relevant receptor associated with 
different neurodegenerative diseases such as AD and prion disease. Serum 
amyloid A (SAA) (Su et al. 1999), the 42-amino acid form of amyloid beta 
(Aβ42) (Le et al. 2001a) and PrP106-126, a 21-amino acid fragment of the 
human prion protein (Le et al. 2001c), have been reported to bind to FPR2. 
The binding of Aβ42 to FPR2 induces superoxide production and monocyte 
chemotaxis to Aβ plaques (Tiffany et al. 2001; Cui et al. 2002b). There is also 
evidence that FPR2 promotes the cellular uptake of Aβ42 which could 
contribute to the formation of Aβ fibrils (Yazawa et al. 2001). PrP106-126 
bound to FPR2 leads to chemotaxis of monocytes to brain lesions caused by 
prions and upregulates the generation of pro-inflammatory TNF-α and 
interleukin-1-beta (IL-1β) (Le et al. 2001c), promoting a pro-inflammatory 
response and contributing to the inflammatory pathology.  
 However, other agonists of FPR2 can oppose these pathogenic effects 
and promote an anti-inflammatory environment. For instance, humanin 
competes with Aβ42 for binding to FPR2, preventing the effect of Aβ42 on 
phagocytes and inhibiting Aβ42 aggregation and subsequent fibrillary 
formation (Ying et al. 2004). Annexin I is upregulated in microglia in AD and 





resolution of inflammatory microglial activation (McArthur et al. 2010).  
LXA4 promotes anti-inflammatory cytokine production while inhibiting that 
of pro-inflammatory cytokines associated with AD progression, and increases 
clearance of Aβ in the brains of transgenic AD mice (Medeiros et al. 2013). A 
role of RvD1 in AD was elucidated by a study demonstrating that 
administration of RvD1 with vitamin D promoted phagocytosis of Aβ and 
prevented apoptosis of macrophages induced by fibrillar Aβ (Mizwicki et al. 
2013). Together, these findings demonstrate that the ability of FPR2 to bind 
anti-inflammatory ligands may be helpful to counter the neurotoxic effects of 
its pathogenic peptide agonists. 
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There has been much recent interest in the omega-3 PUFA DHA due to 
its widely reported anti-inflammatory (Hong et al. 2003) and neuroprotective 
roles (Belayev et al. 2009), as well as effects on cognition and behaviour 
(Innis 2007; Wurtman 2008). Many studies have also demonstrated beneficial 
effects of DHA in learning and memory (Zicker et al. 2012; Kuratko et al. 
2013; Stonehouse et al. 2013). DHA can be metabolised by 15-lipoxygenase 
(15-LOX-1). 15-LOX-1 holds important roles in neuronal function, 
neuroinflammation and neurodegeneration due to the diverse products 
generated from the multiple pathways it participates in. Of these products, 
lipoxins, resolvins and neuroprotectins are lipid mediators that are involved in 
normal brain functions such as regulating synaptic plasticity, as well as 
resolution of inflammation and neuroprotection. Environmental factors can 
influence epigenetic processes in the genome and modify the expression of 
various genes, and these epigenetic modifications are associated with ageing 
and neurodegenerative diseases. Therefore, given the importance of DHA and 
15-LOX-1 in the CNS, it would be of interest to examine the expression and 
distribution, as well as the epigenetic mechanisms of 15-LOX-1 in the CNS. 
In the first chapter of this thesis, an initial screening of the mRNA 
expression of the various LOX isoforms in the brain was examined. Following 
that, Western blot and immunohistochemistry was carried out to elucidate the 
protein distribution and localisation of 15-LOX-1 in the CNS. Liquid 
chromatography mass spectrometry (LC-MS) was used to study RvD1 levels 
after 15-LOX-1 inhibition. In the second chapter, the differential epigenetic 
regulation of 15-LOX-1 is examined in primary cortical neurons and 
undifferentiated neuronal-like SH-SY5Y cells. Primary neurons and SH-SY5Y 
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cells were first treated with HDAC inhibitors to determine any epigenetic 
effects on 15-LOX-1 gene expression. Pretreatment with HAT inhibitors 
before HDAC inhibitors was then carried out to examine the interplay between 
HATs and HDACs in regulating 15-LOX-1 expression. SH-SY5Y cells were 
treated with TSA and 15-LOX-1 inhibitor to examine a possible role of 15-
LOX-1 in cell death mediated by TSA. 
FPRs are a family of GPCRs that are activated as part of the host 
defence in response to bacterial infection. FPR2 is a unique member of this 
family as it is the first receptor demonstrated to bind to various protein and 
lipid ligands such as LXA4 and RvD1. This multi-ligand nature of FPR2 
makes it a receptor of interest particularly in neuroinflammation. LXA4 and 
RvD1 are lipid mediators whose anti-inflammatory and pro-resolving actions 
in the CNS have been demonstrated. Previously, immunohistochemical 
localisation of FPR has been elucidated in the brain, but there is a dearth of 
data on the expression of FPR2 in the CNS. The third chapter of this thesis 
examines the expression, distribution and localisation of FPR2 in the CNS and 
provides a discussion of the findings. It is hoped that this thesis could provide 
a better understanding of 15-LOX-1 and its epigenetic regulation in neurons, 
as well as provide insights into the distribution of FPR2 in the CNS and pave 


























































 The brain is an abundant source of various PUFAs such as DHA and 
these lipids act as substrates for lipid-modifying enzymes such as LOXs. The 
various LOXs are expressed in the CNS and their catalytic activities on the 
different PUFAs produce metabolites that contribute to brain development and 
function. As discussed, 5-LOX is crucial for neuronal development (Manev 
and Uz 1999) and 12S-HETE produced by 12-LOX is involved in synaptic 
modulation (Piomelli et al. 1987a; Piomelli et al. 1987b). 15-LOX and its 
derived products such as 15S-HETE and RvD1 are involved in signalling and 
synaptic functions. In addition, there is evidence to suggest that 15-LOX is 
involved in cognitive functions such as learning and memory (unpublished 
data), possibly through DHA-derived docosanoids (Yurko-Mauro et al. 2010). 
The lipid-oxidising properties of LOXs suggest that they may be 
harmful to the brain during inflammation by propagating lipid peroxidation. 
However, LOXs are also capable of producing lipid mediators that are 
beneficial to the CNS. 5- and 15-LOX action on arachidonic acid and DHA 
result in production of lipoxins, resolvins and neuroprotectins that contribute 
to resolving inflammation and maintaining brain homeostasis. In a chronically 
inflamed brain, the actions of these lipid mediators are crucial in mitigating 
the inflammatory environment and preventing further tissue damage. 
Therefore, while LOXs may contribute to the inflammatory environment in 
the chronically inflamed brain, their ability to resolve inflammation should be 
appreciated as well. 
 The importance of LOXs in inflammation has led to extensive studies 
of this family of enzymes both in vitro and in vivo, and their roles in various 
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neuroinflammatory diseases are particularly well-studied. 5-, 12- and 15-LOX-
1 expression levels are upregulated in aged and diseased brains (Uz et al. 1998; 
Pratico et al. 2004; Chinnici et al. 2007), suggesting roles in ageing and 
neurodegenerative disease. 5-LOX is normally expressed in neurons and glial 
cells (Zhang et al. 2006) and its expression is altered after brain injury (Zhang 
et al. 2006). 5-LOX is also indicated in AD (Ikonomovic et al. 2008; 
Giannopoulos et al. 2014). 12-LOX is expressed in the brain (Nishiyama et al. 
1993; Chinnici et al. 2005) and plays a role in the pathophysiology of AD and 
PD. 15-LOX-1 is involved in AD and oxidative stress, suggesting an 
association between 15-LOX-1 expression and neuroinflammation. However, 
its pathways leading to the generation of anti-inflammatory metabolites such 
as lipoxins, resolvins and neuroprotectins suggest that 15-LOX-1 is 
neuroprotective in the brain during inflammation and disease. In this study, the 
expression levels of 5-LOX, 12-LOX and 15-LOX-1 in the CNS were 
elucidated and the highest-expressing LOX isoform, 15-LOX-1, was subjected 
to further characterisation by Western blot and immunohistochemical studies. 
In addition, 15-LOX-1 was inhibited in the rat prefrontal cortex and analysed 
for RvD1 with LC-MS techniques. 
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1.2 Materials and Methods 
1.2.1 Chemicals 
 15-LOX-1 inhibitor PD146176 was purchased from Cayman Chemical 
(Cayman Chemical, MI, USA).  
 
1.2.2 Animals 
 Adult male Wistar rats (250-300g) were purchased from InVivos, 
Singapore and housed under regulated conditions of 22°C and a 12-hour light-
dark cycle with unrestricted access to food and water. All animals were 
allowed to acclimatise for at least three days before the start of any 
experiments or procedures. All animal procedures were performed in 
accordance with the Principles of Laboratory Animal Care and the 
Institutional Animal Care and Use Committee of the National University of 
Singapore (NUS). 
 
1.2.3 Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
 Four adult male Wistar rats were used for this portion of the study. The 
rats were anaesthetised with intraperitoneal injection of a cocktail of ketamine 
and xylazine (7.5 ml ketamine (75 mg/kg), 5 ml xylazine (10 mg/kg), in 0.9% 
sodium chloride solution) and sacrificed by decapitation. The whole rat brain 
was dissected anatomically to obtain the different parts: olfactory bulb (OB), 
prefrontal cortex (PFC), striatum (STR), hippocampus (HPC), cortices 
(equally dissected and labelled CTX1 and CTX2), thalamus/hypothalamus 
(THA), cerebellum (CB) and brainstem (BS). The spinal cord was dissected in 
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two parts: cervical (SC(C)) and lumbar (SC(L)). Anatomically, CTX1 contains 
the primary and secondary motor cortex and the primary somatosensory cortex, 
whereas CTX2 includes the parietal association cortex and secondary auditory 
cortex. The harvested tissues were snap frozen in liquid nitrogen and stored in 
-80°C. Total RNA was extracted using TRIzol® reagent (Invitrogen, CA, 
USA) according to the manufacturer’s protocol and purified using the RNeasy 
Mini Kit (Qiagen Inc., Hilden, Germany). RNA samples were reverse 
transcribed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, CA, USA). Reaction conditions were 25°C for 10 
minutes, 37°C for 120 minutes and 85°C for 5 minutes. Real-time PCR 
amplification was performed using the 7500 Real-time PCR system (Applied 
Biosystems, CA, USA) using the TaqMan® Universal PCR Master Mix 
(Applied Biosystems, CA, USA), with TaqMan® Gene Expression Assay 
Probes for 5-LOX (Rn00563172_m1), 12-LOX (Rn01461082_m1), 15-LOX-1 
(Rn00696151_m1) and β-actin (#4352340E) (Applied Biosystems, CA, USA). 
PCR reaction conditions were an initial incubation of 50ºC for 2 minutes and 
95ºC for 10 minutes, followed by 40 cycles of 95ºC for 15 seconds and 60ºC 
for 1 minute. All reactions were carried out in triplicates. The amplified 
transcripts were then quantified using the comparative CT method with the 
formula for relative fold change = 2−∆∆CT (Livak and Schmittgen 2001). The 
mean and standard errors were calculated. 
 
1.2.4 Western Blot 
 Proteins were extracted from different parts of the brain and spinal 
cord using T-PER® Tissue Protein Extraction solution containing 1% HaltTM 
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protease inhibitor and 1% EDTA solution (Thermo Fisher Scientific, IL, USA). 
Concentrations of the protein obtained were measured using the Bio-Rad 
protein assay kit. Protein samples (30 µg) were then mixed with a loading dye 
consisting of SDS and DTT before undergoing denaturation at 95–100°C for 
10 minutes and resolved in 10% SDS-polyacrylamide gels under reducing 
conditions. A protein ladder was also used to monitor the electrophoresis run 
and to check for protein size as well as protein transfer efficacy (Precision 
Plus Protein Dual Color Standards, Bio-Rad Laboratories, CA, USA). The 
resolved proteins were then electrotransferred to a polyvinylidene difluoride 
(PVDF) membrane and non-specific binding sites were blocked by incubation 
for 1 hour with 5% non-fat milk in Tris-buffered saline (TBS) containing 0.1% 
Tween-20 (TBST). After blocking, the PVDF membrane was incubated 
overnight with a mouse monoclonal antibody to 15-LOX-1 (ab119774, Abcam, 
New Territories, HK; diluted 1:500 in 5 % non-fat milk in TBST) at 4°C. The 
15-LOX-1 antibody had been used previously to confirm a knockdown of 15-
LOX-1 in rats, confirming the specificity of the antibody to 15-LOX-1 
(Shalini et al. 2016). The PVDF membrane was then washed with TBST and 
incubated with horseradish peroxidase-conjugated anti-mouse IgG (Thermo 
Fisher Scientific, IL, USA; diluted 1:2000 in 5% non-fat milk in TBST) for 1 
hour at room temperature. The protein bands were visualized with an 
enhanced chemiluminescence kit (Supersignal West Pico, Thermo Fisher 
Scientific, IL, USA). For the loading controls, the membrane was incubated 
with a stripping buffer for 10 minutes at room temperature (Restore Western 
Blot Stripping Buffer, Thermo Fisher Scientific, IL, USA). After stripping, the 
membrane was again blocked with 5% non-fat milk in TBST before 
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incubating with a mouse monoclonal antibody to β-actin (Sigma Aldrich, MO, 
USA; diluted 1:10000 in 5% non-fat milk in TBST) for 30 minutes at room 
temperature. The membrane was then incubated with horseradish peroxidase-
conjugated anti-mouse IgG (Thermo Fisher Scientific, IL, USA; diluted 
1:10000 in 5% non-fat milk in TBST) for 30 minutes. Visualisation of the 
protein bands were then carried out. Visualised films containing the protein 
bands were scanned and their densities were measured using the Gel-Pro 
Analyzer 3.1 program (Media Cybernetics, MD, USA). The densities of the 
target bands were normalised against those of β-actin. The means and standard 
errors were then calculated. 
 
1.2.5 Immunohistochemistry 
 Four adult male Wistar rats were used for this portion of the study. 
Rats were deeply anaesthetised and perfused through the left cardiac ventricle 
with a solution of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1M 
phosphate buffer (pH 7.4). The perfused brains were removed and sectioned 
coronally at 100 μm using a vibrating microtome (Leica, Wetzlar, Germany). 
The free-floating sections were washed with phosphate-buffered saline (PBS) 
and incubated overnight at 4°C with 15-LOX-1 antibody (ab119774, Abcam, 
New Territories, HK), diluted 1:50 in PBS. Sections were incubated for 1 hour 
in a 1:200 dilution of biotinylated anti-mouse IgG (Vector Laboratories, Inc., 
CA, USA), followed by an hour incubation with avidin-biotin complex. 
Sections were stained for 15-LOX-1 for 5 minutes using a mixture of 3,3’-
diaminobenzidine tetrahydrochloride (Sigma-Aldrich, MO, USA) in nickel-
TBS containing 0.05% hydrogen peroxide. Stained sections were mounted on 
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glass slides and counterstained with methyl green followed by coverslipping 
for light microscopy viewing. 
 
1.2.6 Transmission Electron Microscopy 
 Electron microscopy was carried out by subdissecting some of the 
immunostained sections into smaller portions. These were post-fixed with 2% 
osmium tetroxide, dehydrated in an ascending series of 25%, 50%, 75%, 95%, 
100% ethanol and 100% acetone. The sections were embedded in Araldite at 
40°C, 50°C and 55°C for 45 minutes each. Thin sections were obtained from 
the first 5 μm of the sections, mounted on copper grids coated with Formvar, 
and stained with lead citrate. They were viewed using a JEOL 1010 EX 
electron microscope (JEOL, Tokyo, Japan). 
 
1.2.7 Liquid Chromatography Mass Spectrometry (LC-MS) 
 Six adult male Wistar rats were used per group (DMSO control, 15-
LOX-1 inhibitor PD146176) in this portion of the study. Rats were 
anaesthetised with ketamine and xylazine, and placed on a stereotaxic 
apparatus (Stoelting, IL, USA). Two small craniotomies were made over the 
PFC on each side, and 2 µl of either DMSO control or 15-LOX-1 inhibitor 
PD146176 (5 μM) was injected using a Hamilton syringe at each site over 5 
minutes (coordinates: 4.0 mm rostral to bregma; 1.5 mm lateral to midline and 
2.0 mm from surface of cortex). Rats were sacrificed 24 hours after surgery 
and the prefrontal cortex collected. 
Tissues were homogenised in 750 µl of Folch solution (2:1 v/v 
chloroform/methanol) with a Tissue Tearor™ (Biospec, OK, USA). Samples 
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were then sonicated for 30 minutes at 4ºC. 200 µl of 0.88% KCl was added to 
samples before vortexing for 1 minute followed by centrifugation at 9000 g for 
2 minutes. The organic portions were then collected and vacuum-dried 
(Thermo Savant SpeedVac, IL, USA). Lipids were resuspended in 200 µl of 
100% Acetonitrile and transferred to an amber glass vial for LC-MS analysis. 
Differences in the amounts of lipid species present were normalised to total 
amount of lipids in each sample and statistical differences analysed with 









1.3.1 Differential expression of LOX isoforms in the CNS 
Figure 1.3.1.1 Real-time RT-PCR analyses of 5-LOX, 12-LOX and 15-LOX-1 
mRNA distribution in various parts of the rat brain and spinal cord. Parts 
include the olfactory bulb (OB), prefrontal cortex (PFC), motor cortex (CTX1), 
parietal association cortex (CTX2), striatum (STR), thalamus/hypothalamus (THA), 
hippocampus (HPC), cerebellum (CB), brainstem (BS), cervical spinal cord (SC(C)) 
and lumbar spinal cord (SC(L)). Fold change values were normalised to the lowest-
expressing 12-LOX in the hippocampus. Data represent the mean and standard error 
of 4 Wistar rats. 
 
Real-time RT-PCR results show that 15-LOX-1 is the highest-
expressing isoform in the rat CNS, compared to 5-LOX and 12-LOX. 15-
LOX-1 expression is generally higher than those of 5-LOX and 12-LOX in all 
parts of the brain and spinal cord. 12-LOX was the lowest expressing isoform 
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Figure 1.3.1.2 Real-time RT-PCR analyses of 15-LOX-1 mRNA distribution in 
various parts of the rat brain and spinal cord. Parts include the olfactory bulb 
(OB), prefrontal cortex (PFC), motor cortex (CTX1), parietal association cortex 
(CTX2), striatum (STR), thalamus/hypothalamus (THA), hippocampus (HPC), 
cerebellum (CB), brainstem (BS), cervical spinal cord (SC(C)) and lumbar spinal 
cord (SC(L)). Fold change values were normalised to the lowest-expressing 15-LOX-
1 in the cerebellum. Data represent the mean and standard error of 4 Wistar rats. 
 
Examining mRNA expression of 15-LOX-1 alone, the highest 
expression was observed in the prefrontal cortex, followed by the parietal 
association cortex (CTX2), cervical spinal cord, lumbar spinal cord, motor 
cortex (CTX1), thalamus/hypothalamus, brainstem, striatum, hippocampus, 
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1.3.2 Western Blot analyses of 15-LOX-1 protein expression in the CNS 
 
 
Figure 1.3.2 Protein expression of 15-LOX-1 in the rat CNS. (A) Immunoblot of 
total proteins resolved from the CNS of adult Wistar rats against 15-LOX-1 antibody. 
Parts analysed include the olfactory bulb (OB), prefrontal cortex (PFC), cortex 1 
(CTX1), motor cortex (CTX1), parietal association cortex (CTX2), striatum (STR), 
thalamus/hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem 
(BS), cervical spinal cord (SC(C)) and lumbar spinal cord (SC(L)). Protein levels of 
β-actin were assayed to verify equal loading of samples. (B) Densitometric analyses 
of 15-LOX-1 band intensities normalised to β-actin. Data represents the mean and 
standard error of 4 Wistar rats. 
 
The 15-LOX-1 antibody detected a single band of 75 kDa in the adult 
rat CNS (Figure 1.3.2A). The observed band size is consistent with the 
reported molecular weight of 15-LOX-1 (Kuhn et al. 2002) and 15-LOX-1 is 
not known to be post-translationally modified (Kuhn et al. 2002). The 
prefrontal cortex was found to have the highest relative protein expression, 
followed by the motor cortex (CTX1), parietal association cortex (CTX2), 
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cerebellum, cervical spinal cord and lumbar spinal cord (Figure 1.3.2B). The 
quantitative densitometric analyses showed similar results to that seen in RT-
PCR, with the exception of the brainstem and spinal cord. 
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Figure 1.3.3 Light micrographs of 15-LOX-1 immunoreactive brain slices in the 
forebrain of 4 adult male Wistar rats. A-H Sections incubated with 15-LOX-1 
antibody. A Olfactory bulb, 60X magnification. B Prefrontal cortex, 10X 
magnification. C Prefrontal cortex, 60X magnification. D Entorhinal cortex, 60X 
magnification. E Striatum, 20X magnification F Hippocampal CA1 field, 60X 
magnification. G Hippocampal CA3 field, 60X magnification. H Dentate gyrus, 60X 
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Figure 1.3.4 Light micrographs of 15-LOX-1 immunoreactive brain slices in the 
hindbrain and spinal cord of 4 adult male Wistar rats. A-D Sections incubated 
with 15-LOX-1 antibody, 20X magnification. A Cerebellum. B Brainstem. C Dorsal 
horn of spinal cord. D Ventral horn of spinal cord. Scale: A-D = 200 μm. 
 
Dense staining was observed mainly in the forebrain including the 
olfactory bulb (Figure 1.3.3A), prefrontal cortex (Figure 1.3.3B and 1.3.3C) 
and entorhinal cortex (Figure 1.3.3D). The striatum was indiscernibly stained 
(Figure 1.3.3E). The hippocampus showed dense immunolabelling, including 
the hippocampal CA1 field (Figure 1.3.3F), CA3 field (Figure 1.3.3G) and 
dentate gyrus (Figure 1.3.3H). Although lighter immunostaining was observed 
in both the cerebellum and the brainstem, the cerebellum (Figure 1.3.4A) 
showed comparatively greater staining than the brainstem (Figure 1.3.4B). The 
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1.3.5 15-LOX-1 localisation in the prefrontal cortex and hippocampus 












Figure 1.3.5 Electron micrographs of 15-LOX-1 immunoreactive sections from 
the prefrontal cortex and hippocampus. Immunolabelling was observed in the 
dendritic spines of postsynaptic neurons and axons of presynaptic neurons in the 
prefrontal cortex (A-C) and hippocampus (D). AT Axon terminal, D dendrite, S 
Synapse. Scale: A-B = 0.2 μm, C-D = 100 nm. 
 
Electron microscopy images reveal 15-LOX-1 immunolabelling in the 
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1.3.6 LC-MS analyses of resolvin D1 levels in the rat PFC after 15-LOX-
1 inhibition 
 
Figure 1.3.6 Changes in resolvin D1 levels in the rat PFC after 15-LOX-1 
inhibition. Data represents the mean and standard error of 6 Wistar rats. Analysed by 
one-way ANOVA with Bonferroni’s multiple comparisons post-hoc test. * indicates 
significant difference relative to DMSO controls, * p < 0.05. 
 
LC-MS analyses showed that RvD1 levels in the rat PFC were reduced 
to approximately 77% compared to DMSO controls (p < 0.05) after 








































 The present study was carried out to examine the expression, 
distribution and localisation of the most abundant LOX isoform, 15-LOX-1, 
across the CNS. Real-time RT-PCR results show that 15-LOX-1 mRNA is the 
highest expressing LOX isoform in all parts of the CNS including the 
olfactory bulb, prefrontal cortex, cerebral cortices, striatum, 
thalamus/hypothalamus, hippocampus, cerebellum, brainstem and spinal cord. 
These findings are consistent with previous studies that have reported 
expression of 15-LOX-1 in the brain (Pratico et al. 2004; van Leyen et al. 
2006). The presence of 5-LOX (Lammers et al. 1996) and 12-LOX 
(Nishiyama et al. 1992) in the olfactory bulb, thalamus, hippocampus, 
cerebellum and brainstem are consistent with previous reports. 5-LOX is 
expressed in glial cells and in neurons (Zhang et al. 2006) and presence of 12-
LOX has been reported in neurons, glial cells and endothelial cells (Nishiyama 
et al. 1993). As 15-LOX-1 was the highest-expressing LOX isoform, Western 
blot and immunohistochemical staining of 15-LOX-1 were carried out. The 
results from Western blot analyses were generally consistent with that of real-
time RT-PCR, with the prefrontal cortex displaying the highest relative protein 
expression of 15-LOX-1. However, the brainstem and spinal cord displayed 
differing results, with high mRNA levels but almost negligible protein levels. 
The 75 kDa band observed in the Western blot is consistent with the reported 
molecular weight of 15-LOX-1 (Kuhn et al. 2002). 
Immunohistochemical staining was carried out to determine the 
distribution and localisation of 15-LOX-1 in the CNS. Light microscopy was 
first used to examine the expression pattern of the 15-LOX-1 protein in 
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various parts of the brain and spinal cord. The dense staining in the forebrain 
indicates a strong presence of 15-LOX-1 protein in these areas, whereas the 
comparatively lighter staining in the thalamus, cerebellum and brainstem 
suggest that 15-LOX-1 protein expression is lower in these areas. In contrast, 
15-LOX-1 is likely expressed in very low levels in the striatum and spinal 
cord given the absence of staining. The low expression levels and 
immunolabelling of 15-LOX-1 in the striatum and cerebellum suggest that 15-
LOX-1 may not be involved in the functions of these areas which includes 
motor initiation (Montgomery and Buchholz 1991) and control (Paulin 1993), 
posture (Ioffe 2013) and balance (Morton and Bastian 2004). Similar to 
Western blot findings, there was light immunolabelling of 15-LOX-1 protein 
in the brainstem and spinal cord. The lack of observable 15-LOX-1 protein 
expression in the brainstem and spinal cord is interesting given the high 
mRNA expression observed and involvement of its PUFA metabolites LXA4 
and RvD1 in spinal cord injury (Xu et al. 2010; Abdelmoaty et al. 2013). It is 
likely that 15-LOX-1 is endogenously lowly expressed in the brainstem and 
spinal cord of naïve rats, given the mRNA expression observed. A possible 
explanation for the absence of 15-LOX-1 protein despite presence of mRNA 
in the hindbrain and spinal cord is that 15-LOX-1 is possibly silenced in these 
areas of the CNS by a mechanism similar to that reported in erythroid cells 
(Ostareck et al. 1997; Ostareck et al. 2001) and the human corneal epithelium 
(Chang et al. 2005). It was reported that in erythrocytes, silencing of 15-LOX-
1 mRNA involves the DICE motif at the 3’-UTR of the 15-LOX-1 gene and 
this silencing is lifted during cell maturation (Ostareck et al. 1997; Ostareck et 
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al. 2001). Therefore, it is possible that 15-LOX-1 is similarly silenced and 
temporally regulated in the hindbrain and spinal cord. 
Taken together, real-time RT-PCR, Western blot and 
immunohistochemical analyses show that 15-LOX-1 is mainly expressed in 
the forebrain. As the prefrontal cortex consistently showed the highest mRNA 
and protein expression and immunolabelling of 15-LOX-1, and 15-LOX-1 
may be involved in the induction of hippocampo-prefrontal cortical LTP 
(unpublished results), TEM was utilised to determine the subcellular 
localisation of 15-LOX-1 in the prefrontal cortex and hippocampus. Electron 
microscopy images reveal 15-LOX-1 immunolabelling in the dendritic spines 
of postsynaptic neurons and axons of presynaptic neurons. These findings are 
supported by a previous study which reported 15-LOX-1 expression in 
neurons (Sun et al. 2015). Dendritic spines are characterised as protrusions 
from the surface of dendritic processes of neurons (Nimchinsky et al. 2002). 
These dendritic spines are a major target for excitatory synaptic input onto 
principal neurons in the hippocampus and neocortex, which make them 
important sites for synaptic transmission and plasticity (Koch and Zador 1993). 
Synaptic plasticity is a physiological phenomenon whereby specific patterns 
of neural activity change the strength of synaptic connections (Martin et al. 
2000), which is thought to underlie learning and memory (Martin et al. 2000), 
two cognitive functions associated with the prefrontal cortex and hippocampus 
(Winocur and Moscovitch 1990; Preston and Eichenbaum 2013; Gilmartin et 
al. 2014). LTP refers to a persistent increase in synaptic efficacy (Shors and 
Matzel 1997) and this phenomenon is associated with synaptic plasticity, 
learning and memory (Sacchetti et al. 2001; Whitlock et al. 2006). N-methyl-
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D-aspartate (NMDA) receptors are involved in the induction of hippocampo-
prefrontal cortical LTP (Jay et al. 1995) and DHA is known to upregulate 
NMDA receptor expression and subsequent NMDA receptor-dependent 
synaptic plasticity (Cao et al. 2009). Previously, iPLA2 in the prefrontal cortex 
was demonstrated to be necessary for synaptic plasticity and induction of 
hippocampo-prefrontal cortical LTP, affecting spatial working memory 
(Shalini et al. 2014). Given that iPLA2 is an upstream enzyme in the DHA 
metabolic pathway through release of DHA from membrane phospholipids, it 
is possible that 15-LOX-1, too, may be involved in synaptic plasticity through 
its DHA metabolites. LC-MS analyses revealed a reduction in RvD1 levels in 
the prefrontal cortex after intracortical administration of 15-LOX-1 inhibitor 
PD146176. This finding is consistent with the role of 15-LOX-1 in producing 
RvD1 from DHA and may have implications on prefrontal cortical functions 
such as cognition (Terrando et al. 2013) and pain modulation (Lorenz et al. 
2003). This is supported by studies showing that RvD1 (Xu et al. 2010) and 
neuroprotectin D1 (Xu et al. 2013) block inflammatory and neuropathic pain 
by normalising spinal cord synaptic plasticity and inhibiting spinal LTP. 
Knockdown of 15-LOX-1 in the rat prefrontal cortex was shown to impair 
spatial working memory and abolished the anti-nociceptive effect of a DHA-
containing nutraceutical formulation in a neuropathic pain model (Shalini et 
al., unpublished data). Therefore, localisation of 15-LOX-1 in dendritic spines 
of postsynaptic neurons suggests that 15-LOX-1 is involved in the modulation 
of synaptic transmission and synaptic plasticity, and DHA metabolites such as 
resolvin D1 and neuroprotectin D1 may be necessary for these effects. 
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Although the frontal and temporal cortices of the brain are affected in 
AD, together with increased 15-LOX-1 in these areas (Pratico et al. 2004), and 
it contributes to oxidative stress in diseased brains (Pallast et al. 2009), the 
high expression of 15-LOX-1 in the forebrain can be beneficial for 
neuroinflammatory and neurodegenerative diseases. Its ability to produce anti-
inflammatory mediators such as lipoxins and resolvins may be useful in 
counteracting against inflammation in these areas. Restoration of LXA4 
signalling has been shown to be beneficial in transgenic AD mice by reducing 
Aβ and improving cognition (Dunn et al. 2015). DHA is the main n-3 fatty 
acid available in neuronal membranes (Svennerholm 1968) and LC-MS results 
show that 15-LOX-1 is involved in metabolising DHA to RvD1. Therefore, 
DHA supplementation can possibly shift the 15-LOX-1 metabolic pathway to 
favour production of RvD1 such that it aids in ameliorating 
neuroinflammation and pathology (Mizwicki et al. 2013). With the high 
expression of 15-LOX-1 in the forebrain, production of LXA4 or 
administration of DHA, which is subsequently converted to RvD1, may aid in 
reversing damage caused by neurodegeneration. These findings may provide 
further insights into the roles of 15-LOX-1 and DHA in disease and the 
neuroprotective potential of its products to improve medical treatment. 
Taken together, 15-LOX-1 is the highest-expressing LOX isoform in 
the rat CNS and its abundant expression in the forebrain may be associated 
with its roles in synaptic plasticity, cognition and disease.  
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 Regulation of gene expression is a complex process that is tightly 
controlled at the chromatin, transcriptional and translational levels, influencing 
the amount of proteins produced which is crucial for proper development of an 
organism. Regulation of chromatin conformation is an important factor for 
gene expression, since the structure of chromatin can affect the binding of 
transcriptional machinery. Chromatin structure can be altered by histone 
modifications and regulation of gene expression in this manner is known as 
epigenetic regulation. 
Transcriptional regulation is a crucial mechanism for expression of 15-
LOX-1 and is the basis for its tissue-specific expression. The 5’-flanking 
promoter region of the human 15-LOX-1 gene contains putative binding sites 
for various transcription factors including signal transducer and activator of 
transcription 6 (STAT6), activator protein 2 (AP-2), GATA motif-binding 
transcription factor 1, nuclear factor 1 (NF-1), and SP-1 (Kelavkar et al. 1998; 
Conrad and Lu 2000; Lee et al. 2001). These binding sites are localised to 
between 20 kb upstream and 10 kb downstream of the transcription initiation 
site (Ivanov et al. 2015). Besides regulation of gene expression by 
transcription factors, various cytokines have been reported to activate 15-
LOX-1, suggesting that 15-LOX-1 may be modulated during inflammation. 
Interleukin-4 (IL-4) and interleukin-13 (IL-13) are well-established activators 
of 15-LOX-1 gene expression in various cells such as monocytes (Conrad et al. 
1992; Roy and Cathcart 1998; Xu et al. 2003), endothelial cells (Lee et al. 
2001) and epithelial cells (Brinckmann et al. 1996). Activation of the cyclic 
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GMP/protein kinase G pathway is also known to induce 15-LOX-1 expression 
in human colon cancer cells (Deguchi et al. 2005). 
In particular, the interaction between cytokines and STAT6 in 15-
LOX-1 gene expression is well-established. IL-4 and IL-13 induction of 15-
LOX-1 gene expression requires STAT6 (Heydeck et al. 1998; Conrad and Lu 
2000). In fact, IL-4 upregulates the HAT activity of p300/CBP, acetylating 
both histones and STAT6 and leading to 15-LOX-1 transcription 
(Shankaranarayanan et al. 2001). These findings demonstrate that acetylation 
of STAT6 is important for 15-LOX-1 gene transcription. 
The involvement of epigenetic mechanisms in 15-LOX-1 transcription 
was further highlighted in a study where histone 3 demethylation by IL-4 was 
suggested as another mechanism by which IL-4 can induce 15-LOX-1 
expression (Han et al. 2014), in addition to acetylation of STAT6. However, 
given the importance of 15-LOX-1 in neuroinflammation and 
neurodegeneration, there is limited data regarding the regulation of 15-LOX-1 
in neurons and neuron-like cells. In this study, we elucidate differential 
epigenetic regulation of 15-LOX-1 in primary cortical neurons and 
undifferentiated SH-SY5Y neuron-like cells using HDAC and HAT inhibitors. 
Results suggest the differentiation stage of neurons is possibly linked to 
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2.2 Materials and Methods 
2.2.1 Materials 
 All reagents were of analytical grade and used as received without 
further purification. Dimethyl sulfoxide (DMSO), trichostatin A (TSA), 
tubacin, C646 and 5’-deoxy-5’-methylthioadenosine (MTA) were obtained 
from Sigma-Aldrich (Sigma-Aldrich, MO, USA). Sodium butyrate (NaBT), 
MS-275 and butyrolactone-3 (MB-3) were obtained from Santa Cruz 
Biotechnology (Santa Cruz Biotechnology, CA, USA). Depsipeptide was 
purchased from ApexBio (ApexBio, TX, USA). NU9056 was obtained from 
Tocris Bioscience (Tocris Bioscience, Bristol, UK). TMP 195 was purchased 
from Axon Medchem (Axon Medchem, Groningen, Netherlands) and 
PD146176 was obtained from Cayman Chemical (Cayman Chemical, MI, 
USA). Stock solutions were prepared in their respective solvents and diluted in 
cell culture medium for treatment. 
 
2.2.2 Cell culture 
 Primary cortical neurons were harvested from E15.5 mouse embryos 
and cultured in Neurobasal medium supplemented with B-27 (Gibco-
Invitrogen, MA, USA) containing 2 mM L-glutamine, 10 μM glutamate, 1.6% 
fetal bovine serum (FBS), 0.4% horse serum and penicillin/streptomycin. On 
days in vitro (DIV) 3, cells were treated with 1 µM cytosine arabinoside (Ara-
C) for 72 hours to inhibit glial proliferation and maintained in serum-free 
Neurobasal medium supplemented with B-27 under standard conditions of 
37°C and 5% CO2. Treatments were conducted on DIV 10-14 (Huang et al. 
2015).  
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SH-SY5Y human neuroblastoma cells (CRL-2266) were obtained from 
the American Type Culture Collection (ATCC®). SH-SY5Y cells were 
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) containing 10% 
FBS and 1% penicillin/streptomycin (Gibco-Invitrogen, MA, USA). SH-
SY5Y cells were maintained in 100 mm dishes (Greiner Bio-One, USA) and 
incubated under standard conditions of 37°C and 5% CO2. They were 
regularly passaged using 25% Trypsin-EDTA (Gibco-Invitrogen, MA, USA). 
 
2.2.3 Primary neuron culture 
2.2.3.1 Treatment of primary neurons with HAT and HDAC 
inhibitors 
 TSA is a pan-HDAC inhibitor that blocks the activity of class I and II 
HDACs (Ropero and Esteller 2007). C646 is a HAT inhibitor that inhibits 
p300 HAT (Bowers et al. 2010), whereas NU9056 is a Tip60 HAT-specific 
inhibitor (Coffey et al. 2012). To examine the effects of HAT and HDAC 
inhibitors on 15-LOX-1 expression, primary neurons were incubated with 
C646 or NU9056 and general HDAC inhibitor TSA. The dosage of the 
compounds used in this study had previously been determined through dose-
dependent experiments and found to be optimal for inducing epigenetic 
changes (Tan et al. 2016). Primary neurons were treated as follows: (1) DMSO 
as vehicle control, (2) 20 μM C646, (3) 20 μM NU9056, (4) 0.5 µM TSA, (5) 
20 μM C646 and 0.5 µM TSA, and (6) 20 μM NU9056 and 0.5 µM TSA. 
Cells were pretreated with HAT inhibitor for 1 hour followed by TSA or 
vehicle treatment for 24 hours. 
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2.2.3.2 Semi-quantitative Reverse Transcriptase Polymerase Chain 
Reaction (RT-PCR) 
 Total RNA from primary neurons (1 μg) was incubated with 200 units of 
MMLV reverse transcriptase (Clontech, CA, USA) in a 20 μl buffer 
containing 50 mM Tris-Cl (pH 8.3), 75 mM KCl, 3 mM MgCl2, 20 units of 
RNase inhibitor, 1 μM polydT oligomer, and 0.5 mM dNTPs. Reaction 
mixture was incubated at 42°C for 1 hour and 94°C for 5 minutes for enzyme 
inactivation. A total of 80 μl DEPC-treated water was added to the reaction 
mixture and 5 μl of the reaction solution was used in the PCR reaction. PCR 
was carried out in a 50 μl final volume containing 200 μM dNTPs, 5 pmole of 
each primer, 1.25 units of Tag polymerase (BRL, MD, USA), 20 mM Tris-Cl 
(pH 8.4), 1.5 mM MgCl2, and 50 mM KCl. The mixture was incubated in a 
thermal cycler for 35 cycles with reaction condition as follows: 94°C for 7 
minutes, repeated cycles of 94°C for 45 seconds; 55°C for 45 seconds, and 
72°C for 90 seconds. Samples were then incubated at 72°C for 7 minutes and 
cooled to 4°C (GeneAmp 2400, CT, USA). A 2% agarose gel was used to run 
PCR products to verify DNA fragment size. Primers used were: 5’-
CAGGGATCGGAGTACACGTT and 5’-GATTGTGCCATCCTTCCAGT 
for 15-LOX-1 (Chen et al. 2014); and 5’-TCCCTCAAGATTGTCAG and 5’-
AGATCCACAACGGATAC for GAPDH. 
 
2.2.3.3 Western Blot 
Subcellular fractions of primary neurons were prepared using the 
ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Fermentas, ON, 
Canada). Western blot was performed as previously described (Tsai et al. 2016) 
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with a mouse monoclonal 15-LOX-1 antibody (1:500, Abcam, New 
Territories, HK). Visualisation of the protein bands were then carried out with 
an enhanced chemiluminescence system (Merck Millipore, MA, USA).  
 
2.2.4 SH-SY5Y cell culture 
2.2.4.1 Treatment of SH-SY5Y cells with HDAC inhibitors 
 SH-SY5Y cells were treated with general HDAC inhibitors TSA and 
sodium butyrate, and specific HDAC inhibitors, MS-275 and depsipeptide, for 
24 hours. Sodium butyrate is a general HDAC inhibitor that is effective at the 
millimolar range (Zhou et al. 2011). MS-275 inhibits HDAC activity at the 
micromolar range (Saito et al. 1999; Hu et al. 2003) and depsipeptide is 
effective at the nanomolar range (Zuo et al. 2008). TMP 195 is a class IIa-
specific HDAC inhibitor with IC50 of less than 100 nM for class IIa HDACs 
(Lobera et al. 2013). Each group consisted of four biological replicates. 
 
2.2.4.2  Treatment of SH-SY5Y cells with HAT inhibitors and TSA 
 The GCN5-specific HAT inhibitor MB-3, Tip60-specific HAT 
inhibitor NU9056 and p300-specific HAT inhibitor C646 were used to study 
the interaction of the various HATs and HDACs on 15-LOX-1 expression. 
SH-SY5Y cells were treated with HAT inhibitor and TSA in four groups: (1) 
Vehicle (DMSO), (2) 0.5 µM TSA, (3) 20 µM HAT inhibitor, and (4) 20 µM 
HAT inhibitor and 0.5 µM TSA. Cells were pretreated with HAT inhibitor for 
1 hour followed by TSA or vehicle treatment for 24 hours. 
 
2.2.4.3 Treatment of SH-SY5Y cells with HAT inhibitors and NaBT 
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 The Tip60-specific HAT inhibitor NU9056 and p300-specific HAT 
inhibitor C646 were used to study the interaction of the various HATs and 
HDACs on 15-LOX-1 expression. SH-SY5Y cells were treated with HAT 
inhibitor and NaBT in four groups: (1) Vehicle (DMSO), (2) 5 mM NaBT, (3) 
20 μM HAT inhibitor, and (4) 20 µM HAT inhibitor and 5 mM NaBT. Cells 
were pretreated with HAT inhibitor for 1 hour followed by NaBT or vehicle 
treatment for 24 hours. 
 
2.2.4.4 Treatment of SH-SY5Y cells with HAT inhibitors and MS-275 
 The Tip60-specific HAT inhibitor NU9056 and p300-specific HAT 
inhibitor C646 were used to study the interaction of the various HATs and 
specific HDACs on 15-LOX-1 expression. SH-SY5Y cells were treated with 
HAT inhibitor and MS-275 in four groups: (1) Vehicle (DMSO), (2) 5 µM 
MS-275, (3) 20 µM HAT inhibitor, and (4) 20 µM HAT inhibitor and 5 µM 
MS-275. Cells were pretreated with HAT inhibitor for 1 hour followed by 
MS-275 or vehicle treatment for 24 hours. 
 
2.2.4.5 Treatment of SH-SY5Y cells with HAT inhibitors and 
depsipeptide 
 The Tip60-specific HAT inhibitor NU9056 and p300-specific HAT 
inhibitor C646 were used to study the interaction of the various HATs and 
specific HDACs on 15-LOX-1 expression. SH-SY5Y cells were treated with 
HAT inhibitor and depsipeptide in four groups: (1) Vehicle (DMSO), (2) 
10nM depsipeptide, (3) 20μM HAT inhibitor, and (4) 20 µM HAT inhibitor 
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and 10 nM depsipeptide. Cells were pretreated with HAT inhibitor for 1 hour 
followed by depsipeptide or vehicle treatment for 24 hours. 
 
2.2.4.6 Treatment of SH-SY5Y cells with MTA and TSA 
 The HMT inhibitor, MTA, and TSA were used to study the interaction 
of HMT and HDACs on 15-LOX-1 expression. Treatments were carried out in 
4 groups: (1) Vehicle (DMSO), (2) 0.5 μM TSA, (3) 200 μM MTA, and (4) 
200 µM MTA and 0.5 μM TSA. Cells were pretreated with MTA for 1 hour 
followed by TSA or vehicle treatment for 24 hours. 
 
2.2.5 Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(qRT-PCR) 
 The RNeasy Mini kit (Qiagen Inc., Hilden, Germany) was used to 
extract total RNA from SH-SY5Y cells. The High-Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, CA, USA) was used to reverse-
transcribe total RNA in a thermal cycler with reaction conditions as follows: 
25°C for 10 minutes, 37°C for 120 minutes, and 85°C for 5 minutes. Real-time 
PCR (RT-PCR) was used to quantify cDNA. Reagents for RT-PCR used were 
TaqMan® Universal PCR Master Mix (Applied Biosystems, CA, USA), with 
TaqMan® Gene Expression Assay Probes for human 15-LOX-1 
(Hs00609608_m1) and β-actin (#4326315E) (Applied Biosystems, CA, USA). 
Real-time PCR was performed on the 7500 Real-Time PCR system (Applied 
Biosystems, CA, USA). Reaction conditions were as follows: an initial 
incubation of 50ºC for 2 minutes and 95ºC for 10 minutes, followed by 40 
cycles of 95ºC for 15 seconds and 60ºC for 1 minute. The relative amount of 
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gene transcript was estimated after normalisation to the endogenous control 
gene, β-actin. β-actin was chosen as the endogenous control as it is not known 
to be affected by epigenetic mechanisms (Makki et al. 2008). Reactions were 
performed in triplicates. The amplified transcripts were then quantified using 
the comparative CT method with the formula for relative fold change = 2
−∆∆CT. 
The means and standard errors were computed and statistical differences 
analysed with one-way ANOVA with Bonferroni’s multiple comparisons post-
hoc test, where p < 0.05 was considered significant. 
 
2.2.6 Immunocytochemistry 
 SH-SY5Y cells were plated at a density of 2 x 105 cells on poly-L-
lysine-coated coverslips placed in 24-well plates. Cells were 80% confluent 
before treatment. After 24 hours, cells were fixed with 4% paraformaldehyde. 
Antigen retrieval was carried out with formic acid for 30 minutes, followed by 
permeabilisation with 0.1% Triton-X for five minutes. Fixed cells were 
blocked in 1% bovine serum albumin (BSA) and incubated at 4°C overnight 
with 15-LOX-1 specific antibody (ab119774, 1:50 in 1% BSA, Abcam, New 
Territories, HK), followed by secondary antibody reaction with anti-mouse 
Alexa Fluor 488 (Applied Biosystems, CA, USA; 1:100 in 1% BSA) for one 
hour at room temperature. Nuclei were labelled and coverslips mounted with 
the Prolong Gold Antifade Mountant DAPI (Invitrogen, CA, USA). After 
overnight drying, images of the samples were taken using a confocal 
microscope (Zeiss, OR, USA). 
 
2.2.7 Quantitative image analysis 
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 To measure the fluorescence intensity of cells between the different 
treatments, a confocal microscope (Zeiss, Jena, Germany) was used to capture 
images at the plane with the best focus. Ten images were captured per 
treatment group. The region around each cell was demarcated and measured 
with the Image J software (Schindelin et al. 2015). Background readings were 
taken by capturing three regions without fluorescence. The net fluorescent 
intensity was calculated according to the following formula: Corrected total 
cell fluorescence (CTCF) = Integrated Density – (Area of selected cell x Mean 
fluorescence of background readings). The net average CTCF values were 
normalised and the means and standard errors were computed. Significant 
differences were analysed with one-way ANOVA with Bonferroni’s multiple 
comparisons post-hoc test, where p < 0.05 was considered significant. 
 
2.2.8 Lactate dehydrogenase (LDH) assay 
 SH-SY5Y cells were plated at a density of 2 x 105 cells in 24-well 
plates, and grown to 80% confluency before treatment. The specific 15-LOX-1 
inhibitor, PD146176, was used for the selective inhibition of 15-LOX-1 
activity before treatment with TSA. After 24 hours, cell viability was assessed 
by colourimetric determination of lactate dehydrogenase (LDH) release, using 
the LDH Cytotoxicity Detection Kit (Roche, Mannheim, Germany. The plate 
was read at an excitation wavelength of 490 nm on the Tecan Infinite® 200 
microplate reader (Tecan Group Ltd., Maennedorf, Switzerland). The 
background absorbance reading was subtracted from the absorbance at 490 nm. 
Three plate readings were taken and the average percentage of cell death was 
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 x 100 
The mean cytotoxicity values from treated groups were normalised against 
vehicle-treated negative controls. The means and standard errors were 
computed and significant differences analysed with one-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test, where p < 0.05 was 
considered significant. 
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Figure 2.3.1 Effect of HAT and HDAC inhibitors on 15-LOX-1 expression in 
primary cortical neurons. (A) Northern blot of 15-LOX-1 mRNA expression in 
primary cortical neurons. (B) Densitometric analysis of mRNA band intensity 
normalised to GADPH. (C) Immunoblot of 15-LOX-1 protein expression. (D) 
Densitometric analysis of protein band intensity normalised to GADPH. Data 
represent the mean and standard error of four biological replicates. Analysed by one-
way ANOVA with Bonferroni’s multiple comparisons post-hoc test. 
 
Treatment with 0.5 µM TSA did not result in any significant increases 
in 15-LOX-1 mRNA and protein expression. Pretreatment with 20 µM C646 
or 20 µM NU9056 before TSA did not significantly alter 15-LOX-1 mRNA 
and protein expression as well (Figure 2.3.1A-D).  
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Figure 2.3.2 Real-time RT-PCR analyses of 15-LOX-1 mRNA expression in SH-
SY5Y cells after treatment with various HDAC inhibitors. (A) General HDAC 
inhibitor TSA. (B) General HDAC inhibitor NaBT. (C) Class I-specific HDAC 
inhibitor MS-275. (D) Class I-specific HDAC inhibitor depsipeptide. (E) HDAC6-
specific inhibitor tubacin. Data represent the mean and standard error of four 
biological replicates. Analysed by Independent t-Test. * indicates significant 
difference relative to DMSO (vehicle) controls, * p < 0.05, *** p < 0.001. 
 
 Significant increases in 15-LOX-1 mRNA expression were observed 
after treatment with 0.5 µM TSA (p < 0.001), 5 mM NaBT (p < 0.001), 5 µM 
MS-275 (p < 0.001) and 10 nM depsipeptide (p < 0.001), compared to vehicle 
controls (Figure 2.3.2A-D). A small but significant increase in 15-LOX-1 
mRNA expression (p < 0.05) was observed after treatment with 15 µM tubacin, 
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specific HDAC inhibitor TMP 195 showed no increase in 15-LOX-1 mRNA 
expression (data not shown). 
 
2.3.3 Effect of MB-3 and TSA on 15-LOX-1 expression in SH-SY5Y 
cells 
 
Figure 2.3.3 Real-time RT-PCR analysis of 15-LOX-1 mRNA expression in SH-
SY5Y cells after treatment with MB-3 and TSA. Data represent the mean and 
standard error of four biological replicates. Analysed by one-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test. * indicates significant difference 
relative to DMSO (vehicle) controls, *** p < 0.001. 
 
 A significant 334.6-fold increase in 15-LOX-1 mRNA expression was 
observed after treatment with 0.5 μM TSA (p < 0.001), compared to vehicle 
(DMSO) controls. However, pretreatment with the GCN5-specific HAT 
inhibitor MB-3 (20 µM) did not affect 15-LOX-1 gene expression induced by 
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Figure 2.3.4 Effect of NU9056 and TSA on 15-LOX-1 expression in SH-SY5Y 
cells. (A) Real-time RT-PCR analysis of 15-LOX-1 mRNA expression. (B) 
Immunocytochemistry of 15-LOX-1 protein expression after treatment. (C) 
Calculated average CTCF of 15-LOX-1 fluorescence intensity after treatment 
calculated in arbitrary fluorescence units (AFU). Scale: 20 μm. Data represent the 
mean and standard error of four biological replicates. Analysed by one-way ANOVA 
with Bonferroni’s multiple comparisons post-hoc test. * indicates significant 
difference relative to DMSO (vehicle) controls, ** p < 0.01, *** p < 0.001. # 
indicates significant difference relative to TSA treatment, ## p < 0.01, ### p < 0.001. 
  
 A significant 480.9-fold increase in 15-LOX-1 mRNA expression was 
observed after treatment with 0.5 μM TSA (p < 0.001), compared to vehicle 
(DMSO) controls. Treatment with 20 μM NU9056 alone did not affect 15-
LOX-1 mRNA expression. Pretreatment with 20 μM NU9056 was observed to 
suppress the TSA-induced increase in 15-LOX-1 mRNA expression by 67.0% 
(p < 0.01) (Figure 2.3.4A).  
 15-LOX-1 immunofluorescence labelling showed localisation of 15-
LOX-1 protein in the cytoplasm of SH-SY5Y cells (Figure 2.3.4B). A 
significant increase in fluorescence intensity was observed after TSA 
incubation (0.5 µM), with an average fluorescence value of 16527 arbitrary 
fluorescence units (AFU), compared to vehicle (DMSO) controls (9880 AFU) 
(p < 0.01). Pretreatment with 20 µM NU0956 significantly reduced the TSA-
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Figure 2.3.5 Effect of C646 and TSA on 15-LOX-1 expression in SH-SY5Y cells. 
(A) Real-time RT-PCR analysis of 15-LOX-1 mRNA expression. (B) 
Immunocytochemistry of 15-LOX-1 protein expression after treatment. (C) 
Calculated average CTCF of 15-LOX-1 fluorescence intensity after treatment 
calculated in arbitrary fluorescence units (AFU). Scale: 20 μm. Data represent the 
mean and standard error of four biological replicates. Analysed by one-way ANOVA 
with Bonferroni’s multiple comparisons post-hoc test. * indicates significant 
difference relative to DMSO (vehicle) controls, *** p < 0.001. # indicates significant 
difference relative to TSA treatment, ### p < 0.001. 
 
 A significant 289.9-fold increase in 15-LOX-1 mRNA expression was 
observed after treatment with 0.5 µM TSA, compared to vehicle (DMSO) 
controls (p < 0.001). Treatment with 20 μM C646 alone did not affect 15-
LOX-1 mRNA expression. Pretreatment with 20 µM C646 suppressed the 
effect of TSA treatment on 15-LOX-1 mRNA expression by 65.7% (p = 0.001) 
(Figure 2.3.5A). 
 15-LOX-1 immunofluorescence labelling showed localisation of 15-
LOX-1 protein in the cytoplasm (Figure 2.3.5B). A significant increase in 
fluorescence intensity was observed after TSA treatment, with an average 
fluorescence value of 14917 AFU, compared to vehicle (DMSO) controls 
(5090 AFU) (p < 0.001). Pretreatment with 20 µM C646 significantly 
abolished the TSA-induced increase in immunofluorescence (10060 AFU) (p 
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2.3.6 Effect of NU9056 and NaBT on 15-LOX-1 expression in SH-
SY5Y cells 
 
Figure 2.3.6 Real-time RT-PCR analysis of 15-LOX-1 mRNA expression after 
treatment with NU9056 and NaBT in SH-SY5Y cells. Data represent the mean and 
standard error of four biological replicates. Analysed by one-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test. * indicates significant difference 
relative to DMSO (vehicle) controls, *** p < 0.001. 
  
 A significant fold increase in 15-LOX-1 mRNA expression was 
observed after treatment with 5 mM NaBT (p < 0.001). However, pretreatment 
with 20 μM NU9056 before incubation with NaBT did not suppress this 
increase in 15-LOX-1 mRNA expression (Figure 2.3.6). 
 







































































Figure 2.3.7 Effect of C646 and NaBT on 15-LOX-1 expression in SH-SY5Y cells. 
(A) Real-time RT-PCR analysis of 15-LOX-1 mRNA expression. (B) 
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Calculated average CTCF of 15-LOX-1 fluorescence intensity after treatment 
calculated in arbitrary fluorescence units (AFU). Scale: 20 μm. Data represent the 
mean and standard error of four biological replicates. Analysed by one-way ANOVA 
with Bonferroni’s multiple comparisons post-hoc test. * indicates significant 
difference relative to DMSO (vehicle) controls, *** p < 0.001. # indicates significant 
difference relative to NaBT treatment, ### p < 0.001. 
 
 A significant 990-fold increase in 15-LOX-1 mRNA expression was 
observed after treatment with 5mM NaBT (p < 0.001). Pretreatment with 20 
μM C646 reduced the NaBT-induced increase in 15-LOX-1 mRNA 
expression by 66.2% (p = 0.004) (Figure 2.3.7A). 
 15-LOX-1 immunofluorescence labelling showed localisation of 15-
LOX-1 protein in the cytoplasm (Figure 2.3.7B). A significant increase in 
fluorescence intensity was observed after NaBT treatment, with an average of 
14073 AFU, compared to vehicle (DMSO) controls (5792 AFU) (p < 0.001). 
Pretreatment with 20 µM C646 significantly abolished the NaBT-induced 
increase in immunofluorescence (7958 AFU) (p < 0.001) (Figure 2.3.7C). 
 
2.3.8 Effect of HAT inhibitors and MS-275 or depsipeptide on 15-





























































Figure 2.3.8 Real-time RT-PCR analyses of 15-LOX-1 mRNA expression after 
treatment with specific HAT and HDAC inhibitors in SH-SY5Y cells. (A) 
NU9056 and MS-275. (B) C646 and MS-275. (C) NU9056 and depsipeptide. (D) 
C646 and depsipeptide. Data represent the mean and standard error of four biological 
replicates. Analysed by one-way ANOVA with Bonferroni’s multiple comparisons 
post-hoc test. * indicates significant difference relative to DMSO (vehicle) controls, 
*** p < 0.001. 
 
 Significant increases in 15-LOX-1 mRNA expression were observed 
after treatment with 5 μM MS-275 (p < 0.001) and 10 nM depsipeptide (p < 
0.001). However, pretreatment with 20 μM NU9056 or 20 μM C646 failed to 
suppress the increases in 15-LOX-1 mRNA expression induced by these 
specific HDAC inhibitors (Figure 2.3.8A-D). 
 



































































































Figure 2.3.9 Effect of MTA and TSA on 15-LOX-1 expression in SH-SY5Y cells. 
(A) Real-time RT-PCR analysis of 15-LOX-1 mRNA expression. (B) 
Immunocytochemistry of 15-LOX-1 protein expression after treatment. (C) 
Calculated average CTCF of 15-LOX-1 fluorescence intensity after treatment 
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and standard error of four biological replicates. Analysed by one-way ANOVA with 
Bonferroni’s multiple comparisons post-hoc test. * indicates significant difference 
relative to DMSO (vehicle) controls, *** p < 0.001. # indicates significant difference 
relative to TSA treatment, ### p < 0.001. 
 
 A significant increase in 15-LOX-1 mRNA expression was observed 
after incubation with 0.5 μM TSA (p < 0.001). Pretreatment with 200 µM 
MTA suppressed the effect of TSA treatment on 15-LOX-1 mRNA expression 
by 49.5% (p < 0.001) (Figure 2.3.9A). 
 15-LOX-1 immunofluorescence labelling showed localisation of 15-
LOX-1 protein in the cytoplasm (Figure 2.3.9B). A significant increase in 
fluorescence intensity was observed after TSA treatment, with an average 
fluorescence value of 9524 AFU, compared to vehicle (DMSO) controls (4194 
AFU) (p < 0.001) compared to vehicle control. Pretreatment with 200 µM 
MTA resulted in a significant decrease of the TSA-induced increase in 
immunofluorescence (6083 AFU) (p < 0.001) (Figure 2.3.9C). 
 
2.3.10 Lactate dehydrogenase assay 
 
Figure 2.3.10 Effect of 15-LOX-1-specific inhibitor PD146176 and TSA on LDH 
release in SH-SY5Y cells. Data represent mean and standard error of four biological 
replicates. Analysed by one-way ANOVA with Bonferroni’s multiple comparisons 
post-hoc test. * indicates significant difference relative to DMSO (vehicle) controls, 
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 0.5 µM TSA caused a significant increase in cytotoxicity by 10.5-fold 
(p < 0.001). Pretreatment with the specific 15-LOX-1 inhibitor PD146176 (1 
µM) before incubation with TSA caused an insignificant 15.9% decrease in 









 This study was carried out to investigate the epigenetic regulation of 
15-LOX-1 in neurons and neuron-like SH-SY5Y cells. Studies on primary 
cultured neurons were first conducted on cortical neurons isolated from E15.5 
mouse embryos. As experiments were conducted on DIV 10-14, these primary 
cortical neurons are considered differentiated mature neurons. Epigenetic 
regulation of 15-LOX-1 was then examined in these differentiated primary 
neurons. Differentiated primary neurons were treated with the general HDAC 
inhibitor TSA (0.5 μM) for 24 hours. Semi-quantitative RT-PCR and Western 
blot show no observable changes in 15-LOX-1 mRNA and protein expressions 
compared to vehicle (DMSO)-treated primary neurons. One-hour pretreatment 
with the p300-specific HAT inhibitor C646 (20 μM) or Tip60-specific HAT 
inhibitor NU9056 (20 μM) before TSA revealed that 15-LOX-1 mRNA and 
protein expressions were similarly unaffected by these epigenetic modifiers. 
These findings suggest that 15-LOX-1 expression is not affected by epigenetic 
modifications in differentiated primary neurons. It is possible that the 
chromatin encoding 15-LOX-1 is in an open conformation and further 
epigenetic modifications would not lead to any further increase in 15-LOX-1 
gene expression. 
 We next compared epigenetic regulation of 15-LOX-1 in 
undifferentiated SH-SY5Y cells. Derived from a bone tumour (Kovalevich 
and Langford 2013), SH-SY5Y cells were used as a model of undifferentiated 
neurons as they are neuronal-like and express immature neuronal markers 
(Pahlman et al. 1984). In marked contrast to primary neurons, quantitative 
results showed that 15-LOX-1 mRNA expression was increased by 
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approximately more than 1000-fold after treatment with general HDAC 
inhibitors TSA and sodium butyrate in SH-SY5Y cells. Our findings in 
undifferentiated SH-SY5Y cells show upregulation of 15-LOX-1 expression 
by class I and II HDAC inhibition. Class I HDACs include HDACs 1, 2, 3 and 
8 (Delcuve et al. 2012). Treatment of undifferentiated SH-SY5Y cells with 
class I-specific HDAC inhibitors MS-275 and depsipeptide revealed that class 
I HDACs are highly involved in 15-LOX-1 expression. A previous study had 
also shown that class I HDAC inhibition similarly increased 15-LOX-1 
expression in colon cancer cells (Zuo et al. 2008), consistent with our findings 
in undifferentiated SH-SY5Y neuron-like cells. In comparison, use of the class 
IIa-specific HDAC inhibitor TMP 195 demonstrated that class IIa HDACs are 
not involved in 15-LOX-1 upregulation in undifferentiated SH-SY5Y cells. 
Furthermore, treatment with the class IIb HDAC6 inhibitor tubacin did not 
upregulate 15-LOX-1 mRNA expression as HDAC6 deacetylates tubulin but 
not histones (Haggarty et al. 2003). Results suggest that class I HDACs, but 
not class IIa HDACs or the class IIb HDAC6, are involved in 15-LOX-1 
expression in undifferentiated SH-SY5Y cells. This is in contrast to our 
observations in primary neurons, where 15-LOX-1 expression is insensitive to 
treatment with HDAC inhibitors. Findings suggest differential epigenetic 
regulation of 15-LOX-1 in differentiated primary neurons and undifferentiated 
SH-SY5Y neuron-like cells. These observations in SH-SY5Y cells are 
consistent with other studies which have reported the HDAC inhibitor-
mediated transcriptional upregulation of 15-LOX-1 in colon (Shureiqi et al. 
1999; Kamitani et al. 2001; Zuo et al. 2008), pancreatic (Hennig et al. 2007) 
and breast (Jiang et al. 2006) cancer cell lines. Previous studies have shown 
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that TSA and sodium butyrate activate the promoter region of 15-LOX-1 and 
increase acetylation of histone H4 in colorectal cancer cell lines (Kamitani et 
al. 2001). Global histone H3 and H4 acetylation (Zuo et al. 2008), as well as 
demethylation of the CpG islands on the 5’ promoter region (Hsi et al. 2005) 
have also been demonstrated to upregulate 15-LOX-1 gene expression. These 
studies of 15-LOX-1 epigenetic regulation in carcinoma cell lines are similar 
to the current findings in SH-SY5Y neuroblastoma cells, suggesting a 
comparable role of 15-LOX-1 in poorly differentiated cells (Il Lee et al. 2011). 
HDAC inhibitors may work with transcription factors to influence gene 
expression in human colon cancer (Shureiqi et al. 2007). Sodium butyrate, 
when incubated together with IL-4, strongly increased 15-LOX-1 expression 
in A549 lung cancer epithelial cells, suggesting that HDAC inhibitors may 
also act synergistically with cytokines to regulate gene expression 
(Shankaranarayanan et al. 2001). 
 The balance between acetylation and deacetylation of histone and non-
histone proteins plays a pivotal role in the regulation of gene expression 
(Ropero and Esteller 2007). The possible involvement of HATs in the 
regulation of 15-LOX-1 by co-treating undifferentiated SH-SY5Y cells with 
specific HAT inhibitors was then elucidated. Treatment with the p300 HAT 
inhibitor C646 together with general HDAC inhibitors TSA or sodium 
butyrate showed that p300 HAT is involved in 15-LOX-1 regulation in SH-
SY5Y cells. This finding is supported by a previous study which elucidated 
the role of p300 HAT in 15-LOX-1 regulation in colon cancer cells (Zuo et al. 
2008). p300 HAT, together with its associated protein CBP, interacts with 
STAT6 (McDonald and Reich 1999). Acetylation of histones by p300 HAT 
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allows IL-4-induced-STAT6 to bind to the promoter, facilitating gene 
transcription of 15-LOX-1 (Shankaranarayanan et al. 2001). Treatment with 
NU9056, a specific Tip60 HAT inhibitor, also modulated the increase in 15-
LOX-1 mRNA and protein expression by TSA. However, NU9056 failed to 
suppress the increase in 15-LOX-1 mRNA expression induced by sodium 
butyrate. The GCN5 HAT inhibitor MB-3 also did not inhibit the increase in 
15-LOX-1 mRNA expression by TSA. The concentration of 20 µM was used 
to ensure consistency with the other HAT inhibitors; however, given that the 
reported IC50 of MB-3 is 100 µM (Biel et al. 2004), it is possible that the 
results observed were due to insufficient inhibition of the GCN5 HAT. 
Nevertheless, this study shows that at a concentration of 20 µM, the GCN5 
HAT is not involved in 15-LOX-1 gene regulation. Both p300 and Tip60 HAT 
inhibitors did not suppress the increase in 15-LOX-1 expression by MS-275 
and depsipeptide. Results suggest there could be certain histone acetylations 
on the 15-LOX-1 gene that are increased by HDAC inhibitors MS-275 and 
depsipeptide that are not affected by the p300 and Tip60 HAT inhibitors. 
 As TSA can induce trimethylation of H3K4 to activate gene 
transcription (Pufahl et al. 2012), it was of interest to determine if 15-LOX-1 
transcriptional regulation would be affected by histone methylation. MTA is a 
general histone methyltransferase inhibitor whose mechanism involves 
inhibiting H3K4 methylation (Huang et al. 2006). Pretreatment with MTA 
followed by TSA showed a suppression of TSA-induced 15-LOX-1 
expression at the mRNA and protein level, suggesting that H3K4 
trimethylation is involved in 15-LOX-1 transcriptional activation. These 
findings are supported by a previous study which demonstrated that inhibiting 
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a methyltransferase known as SET and MYND domain-containing protein 3 
(SMYD3) resulted in reduced H3K4 trimethylation and, therefore, suppressed 
15-LOX-1 gene expression (Liu et al. 2012). These findings suggest that 15-
LOX-1 may be regulated via histone methylation in addition to histone 
acetylation. 
 SH-SY5Y cells were treated with epigenetic modifiers to determine 
their effects on cell viability. Treatment with TSA caused significant cell death 
of SH-SY5Y cells, evidenced by the high levels of LDH released. This is 
consistent with previous studies that TSA is detrimental to neuronal cell 
viability (Wang et al. 2009). SH-SY5Y cells were next pretreated with the 
specific 15-LOX-1 inhibitor PD146176 before TSA to examine whether 15-
LOX-1 is involved in TSA-mediated cell death. Results showed that 
PD146176 pretreatment did not significantly affect cell death induced by TSA, 
suggesting that 15-LOX-1 is not involved in TSA-mediated cell death, unlike 
cPLA2 which was previously shown to be involved in cell death caused by 
TSA (Tan et al. 2016). 
 The current findings of insensitivity of primary neurons to epigenetic 
modification of 15-LOX-1 compared to 15-LOX-1 in undifferentiated SH-
SY5Y neuron-like cells suggests a differential response between fully 
differentiated and undifferentiated neurons to epigenetic modifications. The 
developing prenatal brain is highly sensitive to environmental influences and 
epigenetic modifications which can affect gene expression in undifferentiated 
cells (Fagiolini et al. 2009). In contrast, differentiated mature neurons are less 
responsive to such influences due to decreased plasticity associated with 
ageing (Mychasiuk 2015). This is supported by studies which have revealed 
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substantial epigenetic activity in the prenatal period followed by a noticeable 
decline after birth which continues with age (Mychasiuk 2015). Epigenetic 
marks resulting from environmental factors may influence the development of 
neuronal circuits in the developing brain and affect functions such as learning 
and memory. Increased histone acetylation and improvement in memory has 
been associated with environmental enrichment (Fischer et al. 2007). Such 
environmental factors may influence epigenetic mechanisms which affect gene 
expression and plasticity of the developing brain (Fagiolini et al. 2009). In 
view of the results of this study, we hypothesise that some of the epigenetic 
influences on learning and memory may take the form of effects on DHA 
metabolism by 15-LOX-1 and its enzymatic products. DHA is crucial for 
functional development of the brain (Horrocks and Yeo 1999; Innis 2007) and 
the findings of this study suggest that environmental influences may increase 
the expression of 15-LOX-1 in undifferentiated and developing neurons, 
allowing these neurons to metabolise DHA more efficiently. 
 In conclusion, the results of this study suggest that 15-LOX-1 is 
transcriptionally regulated by epigenetic mechanisms in undifferentiated 
neurons. Treatment of undifferentiated SH-SY5Y neuron-like cells with 
general and specific HDAC inhibitors such as TSA, MS-275 and TMP 195 
suggest that 15-LOX-1 is mainly regulated by class I HDACs, and not class II 
HDACs, and co-treatment with specific p300 and Tip60 HAT inhibitors C646 
and NU9056 suggest that HDACs and HATs co-operate to regulate 15-LOX-1 
expression in undifferentiated neuron-like cells. Results suggest that neurons 
early in development are highly vulnerable to epigenetic modifications that 
may arise from environmental influences. 
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There is increasing evidence that inflammation may be modulated by 
endogenously produced lipids that actively participate in suppressing host 
inflammatory responses to infection and injury, resulting in active resolution 
of the inflammatory process (Serhan and Savill 2005). During the early phase 
of inflammation, arachidonic acid is released from membrane phospholipids 
by cPLA2 (Ong et al. 1999) and metabolised to pro-inflammatory 
prostaglandins and leukotrienes (Granstrom 1984). As inflammation 
progresses and begins to resolve, arachidonic acid metabolism switches to 
production of the pro-resolving and anti-inflammatory lipoxins (Levy et al. 
2001), promoting homeostasis (Serhan et al. 2008). Besides arachidonic acid, 
DHA is another PUFA that is beneficial for the CNS due to its extensively 
reported effects on synaptic transmission (Tanaka et al. 2012), synaptic 
plasticity (Wu et al. 2008) and cognitive functions such as learning and 
memory (Hooijmans et al. 2009; Yurko-Mauro et al. 2010) in the CNS. DHA 
is the most abundant fatty acid in neural membranes (Piomelli et al. 2007) and 
is released by iPLA2. The combined actions of 15-LOX-1 and 5-LOX 
produces LXA4 (Serhan et al. 1984) and RvD1 from arachidonic acid and 
DHA, respectively. LXA4 are dual anti-inflammatory and pro-resolving lipid 
mediators that promote resolution of inflammation by inhibiting chemotaxis of 
neutrophils (Serhan et al. 1995; Fierro et al. 2003) and promoting the 
recruitment of macrophages to sites of infection to clear cellular debris (El 
Kebir et al. 2007; Prieto et al. 2010). Furthermore, LXA4 suppresses the 
production of pro-inflammatory cytokines (Wu et al. 2011; Wu et al. 2014) 
and recently has been shown to inhibit microglial activation and reduce 
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neuropathic pain in a rat model through FPR2 (Martini et al. 2016). Similar to 
LXA4, RvD1 is a potent pro-resolving lipid mediator that suppresses 
neutrophil recruitment to inflammatory sites (Norling et al. 2012). 
Furthermore, RvD1 was demonstrated to protect against cognitive decline 
induced by surgery (Terrando et al. 2013), suggesting beneficial effects on 
cognition. Both LXA4 and RvD1 are known ligands of the GPCR formyl-
peptide receptor 2 (FPR2). 
FPR2 is a receptor for bacterial peptides that trigger an immune 
response upon binding, leading to the chemotaxis of phagocytic cells to sites 
of bacterial invasion or tissue damage (Le et al. 2002). However, the role of 
FPR2 extends beyond that of being a chemotactic receptor. Emerging 
evidence has demonstrated that FPR2 is a receptor for a large number of 
protein and lipid ligands which exert various downstream effects (Fiore et al. 
1994; Le et al. 2001b; Migeotte et al. 2006). Some of these ligands are 
associated with inflammation and human diseases, rendering FPR2 an 
important receptor for the study of pathophysiology.  
The important biological implications of FPR2 in neuronal cells and 
tissues are exemplified by the ability of FPR2 to bind protein and lipid ligands 
associated with neuroprotection and neurotoxicity. Some of the protein and 
lipid ligands are endogenous in nature, such as annexin I (McArthur et al. 
2010), humanin (Ying et al. 2004), LXA4 (Medeiros et al. 2013) and RvD1 
(Mizwicki et al. 2013); others are pathogenic in nature, such as Aβ42 (Le et al. 
2001a) and the prion protein fragment PrP106-126 (Le et al. 2001c). Binding 
of pathogenic agonists to FPR2 induces chemotaxis of phagocytes and 
microglia and increases the production of neurotoxic and pro-inflammatory 
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mediators such as TNF-α and IL-1β (Medeiros et al. 2013), exacerbating local 
inflammatory responses and tissue injury. However, these inflammatory 
responses may be opposed by binding of anti-inflammatory agonists such as 
humanin (Ying et al. 2004), annexin I (McArthur et al. 2010), LXA4 
(Hachicha et al. 1999; Kure et al. 2010) and RvD1 (Mizwicki et al. 2013) to 
the same receptor.  
The various findings demonstrate the significance of the role of FPR2 
in normal brain physiology and neuropathophysiology. Immunohistochemical 
localisation of FPR1 has been demonstrated previously in the human brain, 
with positive staining observed in the cortical pyramidal neurons, cerebellum, 
thalamus, spinal trigeminal neurons, and variable staining of the hippocampus 
(Becker et al. 1998). In the mouse brain, the presence of three FPR family 
members, Fpr1, Fpr-rs1 and Fpr-rs2, have been reported in the hippocampus 
and hypothalamus (John et al. 2007). However, expression and distribution 
studies of FPR2 in the CNS are limited. This study was therefore carried out to 
elucidate the relative expression, distribution and localisation of FPR2 in the 
rat CNS. The distribution of FPR2 in the CNS may be useful in understanding 
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3.2 Materials and Methods 
3.2.1 Animals 
 Adult male Wistar rats (250-300g) were purchased from InVivos, 
Singapore and were housed under regulated conditions of 22°C and a 12-hour 
light-dark cycle with unrestricted access to food and water. All animals were 
allowed to acclimatise for at least three days before the start of any 
experiments or procedures. All animal procedures were performed in 
accordance with the Principles of Laboratory Animal Care and the 
Institutional Animal Care and Use Committee of the National University of 
Singapore (NUS). 
 
3.2.2 Real-Time Reverse Transcriptase Polymerase Chain Reaction 
(RT-PCR) 
 Four adult male Wistar rats were used for this portion of the study. The 
rats were anaesthetised with intraperitoneal injection of a cocktail of ketamine 
and xylazine (7.5 ml ketamine (75 mg/kg), 5 ml xylazine (10 mg/kg), in 0.9% 
sodium chloride solution) and sacrificed by decapitation. The whole rat brain 
was dissected anatomically to obtain the different parts: olfactory bulb (OB), 
prefrontal cortex (PFC), striatum (STR), hippocampus (HPC), motor cortex 
and primary somatosensory cortex (CTX1), parietal association cortex and 
secondary auditory cortex (CTX2), thalamus/hypothalamus (THA), 
cerebellum (CB) and brainstem (BS). The spinal cord was dissected in three 
parts: cervical (SC(C)), thoracic (SC(T)) and lumbar (SC(L)). The harvested 
tissues were snap frozen in liquid nitrogen. Total RNA was extracted using 
TRIzol® reagent (Invitrogen, CA, USA) according to the manufacturer’s 
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protocol and purified using the RNeasy Mini Kit (Qiagen Inc., Hilden, 
Germany). Samples were treated with RNase-Free DNase (Qiagen Inc., Hilden, 
Germany) to remove any contaminating DNA. RNA samples were reverse 
transcribed using the High-Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems, CA, USA). Reaction conditions were 25°C for 10 
minutes, 37°C for 120 minutes and 85°C for 5 minutes. Real-time PCR 
amplification was performed using the 7500 Real-time PCR system (Applied 
Biosystems, CA, USA) using the TaqMan® Universal PCR Master Mix 
(Applied Biosystems, CA, USA), with TaqMan® Gene Expression Assay 
Probes for FPR2 (Rn03037051_gH) and β-actin (#4352340E) (Applied 
Biosystems, CA, USA). PCR reaction conditions are as follows: incubation at 
50ºC for 2 minutes and 95ºC for 10 minutes, followed by 40 cycles of 95ºC for 
15 seconds and 60ºC for 1 minute. All reactions were carried out in triplicates. 
The amplified transcripts were then quantified using the comparative CT 
method as previously described (Livak and Schmittgen 2001). The mean and 
standard errors were calculated. 
 
3.2.3 Western Blot 
Proteins were first extracted from the brain and spinal cord using T-
PER® Tissue Protein Extraction solution containing 1% HaltTM protease 
inhibitor and 1% EDTA solution (Thermo Fisher Scientific, IL, USA). 
Concentrations of the protein obtained were measured using the Bio-Rad 
protein assay kit. Protein samples (30 µg) were then mixed with a loading dye 
consisting of SDS and DTT before undergoing denaturation at 95 – 100 °C for 
10 minutes and resolved in 10% SDS-polyacrylamide gels under reducing 
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conditions. A protein ladder was also used to monitor the electrophoresis run 
and to check for protein size as well as protein transfer efficacy (Precision 
Plus Protein Dual Color Standards, Bio-Rad Laboratories, CA, USA). The 
resolved proteins were then electrotransferred to a PVDF membrane and non-
specific binding sites were blocked by incubation for 1 hour with 5% non-fat 
milk in TBST. After blocking, the PVDF membrane was incubated overnight 
with FPR2 antibody (NLS1878, Novus Biologicals, CO, USA; diluted 1:1000 
in 5% non-fat milk in TBST) at 4°C. Peptide competition assay was carried 
out with 5× protein concentration of the peptide antigen (NLS1878PEP, 
Novus Biologicals, CO, USA). The PVDF membrane was then washed with 
TBST and incubated with horseradish peroxidase-conjugated anti-rabbit IgG 
(Thermo Fisher Scientific, IL, USA; diluted 1:2000 in 5% non-fat milk in 
TBST) for 1 hour at room temperature. The protein bands were visualized 
with an enhanced chemiluminescence kit (Supersignal West Pico, Thermo 
Fisher Scientific, IL, USA). For the loading controls, the membrane was 
incubated with a stripping buffer for 10 minutes at room temperature (Restore 
Western Blot Stripping Buffer, Thermo Fisher Scientific, IL, USA). After 
stripping, the membrane was again blocked with 5% non-fat milk in TBST 
before incubating with a mouse monoclonal antibody to β-actin (Sigma 
Aldrich, MO, USA; diluted 1:10000 in 5% non-fat milk in TBST) for 30 
minutes at room temperature. The membrane was then incubated with 
horseradish peroxidase-conjugated anti-mouse IgG (Thermo Fisher Scientific, 
IL, USA; diluted 1:10000 in 5% non-fat milk in TBST) for 30 minutes. 
Visualisation of the protein bands were then carried out. Visualised films 
containing the protein bands were scanned and their densities were measured 
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using the Gel-Pro Analyzer 3.1 program (Media Cybernetics, MD, USA). The 
densities of the target bands were normalised against those of β-actin. The 
means and standard errors were then calculated. 
 
3.2.4 Immunohistochemistry 
 Four adult male Wistar rats were used for this portion of the study. 
Rats were deeply anaesthetised and perfused through the left cardiac ventricle 
with a solution of 4% paraformaldehyde and 0.1% glutaraldehyde in 0.1M 
phosphate buffer (pH 7.4). The perfused brains were removed and sectioned 
coronally at 100 μm using a vibrating microtome (Leica, Wetzlar, Germany). 
The free-floating sections were washed with repeated changes of PBS for 3 
hours and incubated overnight with an affinity-purified rabbit polyclonal 
antibody to FPR2 (NLS1878, Novus Biologicals, CO, USA), diluted 1:500 in 
PBS. Peptide competition assay was carried out using the antigen-absorbed 
antibody as described above. Sections were incubated for 1 hour in a 1:200 
dilution of biotinylated anti-rabbit IgG (Vector Laboratories, Inc., CA, USA), 
followed by one hour incubation with avidin-biotin complex. Sections were 
stained for FPR2 for 20 minutes using a mixture of 3,3’-diaminobenzidine 
tetrahydrochloride (Sigma-Aldrich, MO, USA) with 0.2% nickel ammonium 
sulfate in TBS containing 0.05% hydrogen peroxide. Stained sections were 
mounted on glass slides and counterstained with methyl green followed by 
coverslipping for light microscopy viewing. Unmounted sections were 
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3.2.5 Transmission Electron Microscopy 
 Electron microscopy was carried out by subdissecting some of the 
immunostained sections into smaller portions. These were post-fixed with 2% 
osmium tetroxide, dehydrated in an ascending series of 25%, 50%, 75%, 95%, 
100% ethanol and 100% acetone. The sections were embedded in Araldite at 
40°C, 50°C and 55°C for 45 minutes each. Thin sections were obtained from 
the first 5 μm of the sections, mounted on copper grids coated with Formvar, 
and stained with lead citrate. They were viewed using a JEOL 1010 EX 














3.3.1 Differential expression of FPR2 mRNA in the rat CNS 
 
Figure 3.3.1 Real-time RT-PCR analyses of FPR2 mRNA distribution in various 
parts of the rat brain and spinal cord. Parts include the olfactory bulb (OB), 
prefrontal cortex (PFC), motor cortex (CTX1), parietal association cortex (CTX2), 
striatum (STR), thalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem 
(BS), cervical spinal cord (SC(C)), thoracic spinal cord (SC(T)) and lumbar spinal 
cord (SC(L)). Fold change values were normalised to the lowest-expressing FPR2 in 
the striatum. Data represents the mean and standard error from 4 Wistar rats. 
  
 The relative expression levels of FPR2 mRNA in the brain and spinal 
cord were measured by real-time RT-PCR. Results indicate that, relative to the 
lowest-expressing striatum (STR), the brainstem (BS) exhibited the highest 
level of FPR2 mRNA, followed by the lumbar spinal cord [SC(L)], cervical 
spinal cord [SC(C)], thalamus (THA), thoracic spinal cord [SC(T)] and 
prefrontal cortex (PFC). In contrast, the olfactory bulb (OB), hippocampus 
































Expression of FPR2 mRNA in the CNS
Chapter III 
Characterisation of the Lipoxin/Resolvin Receptor Formyl-Peptide Receptor 2 
110 
 
3.3.2 Western Blot analyses of FPR2 protein expression in the rat CNS
Figure 3.3.2 Protein expression of FPR2 in the rat CNS. (A) Immunoblot of total 
proteins resolved from the CNS of adult Wistar rats against FPR2 antibody. Parts 
analysed include the olfactory bulb (OB), prefrontal cortex (PFC), cortex 1 (CTX1), 
motor cortex (CTX1), parietal association cortex (CTX2), striatum (STR), 
thalamus/hypothalamus (THA), hippocampus (HPC), cerebellum (CB), brainstem 
(BS), cervical spinal cord (SC(C)), thoracic spinal cord (SC(T)) and lumbar spinal 
cord (SC(L)). Protein levels of β-actin were assayed to verify equal loading of 
samples. Blots incubated with antigen-absorbed antibody showed reduced band 
intensities. (B) Densitometric analyses of FPR2 band intensity that were normalised 
to β-actin. Data represents the mean and standard error of 4 Wistar rats. 
 
 From Western blot analysis, the FPR2 antibody detected two major 
bands and one diffuse band (Figure 3.3.2A). The major band of approximately 
38 kDa and the diffuse band of 39 kDa represent the non-glycosylated form of 
FPR2. The other major 55 kDa band is likely a glycosylated form of FPR2. 
Similar modifications have been reported for other FPR isoforms, namely 
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1985; Wenzel-Seifert and Seifert 2003), and this has been shown to account 
for the broad distribution and unique migration patterns of FPRs on SDS-
PAGE gels (Wenzel-Seifert and Seifert 2003; Schneider et al. 2012). 
Quantitative densitometric analyses revealed the brainstem had the highest 
expression of FPR2 protein, followed by the cervical spinal cord, thalamus, 
lumbar spinal cord, cerebellum, primary and secondary motor cortex and the 
primary somatosensory cortex (CTX1), parietal association cortex and 
secondary auditory cortex (CTX2), thoracic spinal cord, prefrontal cortex, 
hippocampus, striatum and olfactory bulb (Figure 3.3.2B). Blots incubated 
with antigen-absorbed antibody showed reduced bands, confirming the 
specificity of the antibody. 
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Figure 3.3.3 Light micrographs of FPR2 immunoreactive brain slices in the 
forebrain of 4 adult male Wistar rats. A-B Sections from the striatum (A) and 
hippocampus (B) incubated with FPR2 blocking peptide antigen-absorbed antibody, 
showing absence of immunostaining, 10X magnification. C-L Sections incubated 
with FPR2 antibody. C Olfactory bulb, 10X magnification. D Cortex, 10X 
magnification. E Cortex, 20X magnification. F Septum, 10X magnification. G 
Striatum, 20X magnification. H Striatum and globus pallidus, 20X magnification. I 
Hippocampus, 10X magnification. J Hippocampus, 20X magnification. K Dentate 
granule neuron dendrites, 100X magnification. L Dentate granule neuron mossy 
fibers, 100X magnification. Scale: A-D, F, I = 200 μm, E, G, H, J = 100 μm, K, L = 
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Figure 3.3.4 Light micrographs of FPR2 immunoreactive brain slices in the 
hindbrain and spinal cord of 4 adult male Wistar rats. A Sections from the 
brainstem incubated with FPR2 blocking peptide antigen-absorbed antibody, showing 
absence of immunostaining, 10X magnification. B-H Sections incubated with FPR2 
antibody. B Cerebellar cortex, 20X magnification. C Deep cerebellar nuclei, 10X 
magnification. D Facial motor nucleus, 10X magnification. E Spinal trigeminal 
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horn of spinal cord, 100X magnification. H Ventral horn of spinal cord, 10X 
magnification. Scale: A, C-F, H = 200 μm, B = 100 μm, G = 50 μm. 
  
 Sections incubated with antibody neutralised by the blocking peptide 
showed absence of immunostaining (Figure 3.3.3A, 3.3.3B, 3.3.4A). Light 
staining was observed in the neuronal cell bodies of the olfactory bulb (Figure 
3.3.3C). Layers III and V of the cortex were densely stained (Figure 3.3.3D-E). 
The septum contained few lightly stained cells (Figure 3.3.3F). The caudate 
putamen of the striatum (Figure 3.3.3G) was densely labelled, however, the 
globus pallidus was unlabelled (Figure 3.3.3H). The hippocampus was 
variably labelled, with generally light staining in the CA fields (Figure 3.3.3I-J) 
and denser staining in the dentate granule neuron dendrites (Figure 3.3.3K) 
and dentate granule neuron mossy fibers (Figure 3.3.3L). In the hindbrain, 
dense staining was observed in the cerebellar cortex (Figure 3.3.4B) and deep 
cerebellar nuclei (Figure 3.3.4C). The facial motor nucleus (Figure 3.3.4D), 
spinal trigeminal nucleus (Figure 3.3.4E) and periaqueductal gray (Figure 
3.3.4F) were densely stained. The dorsal horn of the spinal cord was strongly 
labelled (Figure 3.3.4G) compared to the ventral horn (Figure 3.3.4H). 
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Figure 3.3.5 Electron micrographs of FPR2 immunoreactive sections from the 
prefrontal cortex. Staining is observed in A,C axon terminals (AT) and A,B 
dendrites (D). The labelled axon pre-terminals contained synaptic vesicles but did not 
form synaptic contacts with dendrites. S Immature synapse with labelled axon pre-
terminal. Scale = 100 nm. 
 
 Electron microscopy of immunostained sections of the prefrontal 
cortex showed staining in immature axon pre-terminals (Figure 3.3.5A and 
3.3.5C) and occasional staining in dendrites (Figure 3.3.5A and 3.3.5B). The 
labelled axon terminals contained synaptic vesicles, but often did not form 
mature synaptic contacts with dendrites. The results suggest that FPR2 may be 
















 The present study was carried out to elucidate the expression and 
distribution of FPR2 in different regions of the brain and spinal cord, in order 
to understand possible differential functions of this receptor in the CNS. Real-
time RT-PCR results indicate that FPR2 mRNA is generally present 
throughout the brain, with higher expression in the forebrain (prefrontal cortex 
and thalamus), hindbrain (brainstem) and spinal cord, and relatively lower 
mRNA expression in the olfactory bulb, striatum, hippocampus and 
cerebellum. A relatively higher expression of FPR2 in these regions suggests 
that LXA4 and/or RvD1 may display higher activities in those areas of the 
CNS. The expression of FPR2 in the thalamus is consistent with previous 
findings of mRNA expression of the murine orthologues, Fpr-rs1 and Fpr-rs2, 
in the hypothalamus (Sahni et al. 2004; John et al. 2007). FPR2 is highly 
expressed in the spinal cord, which is consistent with findings from a previous 
study which showed presence of FPR2 mRNA in the naïve rat spinal cord 
(Abdelmoaty et al. 2013).  
 Western blot results were generally consistent with the real-time RT-
PCR results, with the exception of the cerebellum. FPR2 is known to be 
heterogeneously glycosylated, which increases its molecular size of FPR2 to 
different extents. FPR2 exists as a mixture of glycosylated and non-
glycosylated species and this is evident by its migration pattern on SDS-PAGE 
gels. The two bands of 38 kDa and 39 kDa represent the non-glycosylated 
form of FPR2. The 38 kDa band is consistent with the expected molecular 
weight of FPR2, and the diffuse 39 kDa band is also likely the non-
glycosylated form of FPR2. It is unknown why non-glycosylated FPR2 
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migrates as two bands, but unique migration of GPCRs on SDS-PAGE gels 
has been previously reported as well (Grunewald et al. 1996; Kelley et al. 
2001; Houston et al. 2002; Wenzel-Seifert and Seifert 2003). The other band 
of approximately 55 kDa is postulated to be a glycosylated form of FPR2. 
While few studies have elucidated the glycosylation status of FPR2, 
glycosylated forms of FPR2 have been reported previously (Singh et al. 2013). 
Conserved N-glycosylation sites are found on the human FPR2 protein at the 
N-terminus (Asn4) and second extracellular loop (Asn179) (Fiore et al. 1994), 
thus it is likely the rat orthologue possesses these sites as well. Furthermore, 
various other studies have reported the glycosylation status of members of the 
FPR family. For instance, human FPR1 is glycosylated at the N-terminus and 
this glycosylation is necessary for its proper folding (Wenzel-Seifert and 
Seifert 2003). The atypical migration pattern of human FPR1 in SDS-PAGE 
gels, where more than a single band of protein appears, is attributed to the 
existence of FPR1 as a mixture of non-glycosylated and differently-
glycosylated GPCR species (Wenzel-Seifert and Seifert 2003; Schneider et al. 
2012). This may explain the similar separation of FPR2 in SDS-PAGE gels. 
The status of glycosylation of FPR1 is species and cell type-specific, and may 
explain the broad range of molecular masses observed on SDS-PAGE gels 
(Malech et al. 1985). For example, a clone of the Chinese hamster ovary cell 
line revealed that FPR1 was non-glycosylated in this cell line (Wenzel-Seifert 
and Seifert 2003), whereas only the glycosylated form of FPR1 exists in 
human neutrophils (Schneider et al. 2012). Different-sized bands of FPR1 
have also been observed in other cell lines, supporting the possibility that 
FPRs are differently glycosylated in different species and cell types (Schneider 
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et al. 2012). A wide range of molecular weights of FPR2 on SDS-PAGE gels 
has been reported in the literature, ranging from 38 to 100 kDa, which is 
attributed to glycosylation or dimerisation (Gavins et al. 2003; Cooray et al. 
2013; Hodges et al. 2016). Findings show that FPR2 may exist as a mixture of 
both glycosylated and non-glycosylated forms in the naïve rat CNS.  
 Immunohistochemical analyses revealed that pyramidal neurons in 
cortical layers III and V were densely labelled. Pyramidal neurons are lined 
with dendritic spines on their surface that act as postsynaptic sites for 
excitatory glutamatergic synapses (Spruston 2008). Pyramidal neurons have 
important roles in cognitive functions and it has been shown that prefrontal 
cortical pyramidal neurons have extensive dendritic spines on their surface 
that have been proposed to contribute to advanced cognitive processing 
(Elston 2003). Localisation of FPR2 on pyramidal neurons may suggest a role 
of FPR2 in cognitive functions. The hippocampal mossy fiber dendrites of the 
dentate gyrus were also strongly stained. Axons of the dentate granule neurons 
transmit input to the CA3 field of the hippocampus via the mossy fiber 
synapses and are involved in synaptic plasticity of the hippocampus (Nicoll 
and Schmitz 2005). Immunoreactivity to FPR2 in the cortex and hippocampal 
mossy fiber terminals could indicate a role of FPR2 in prefrontal cortical and 
hippocampal synaptic plasticity which underlies cognition, learning and 
memory (Laroche et al. 2000). LXA4 was shown to improve learning and 
memory after subarachnoid haemorrhage and these effects were mediated via 
FPR2 (Guo et al. 2016), whereas another study demonstrated the protective 
effects of RvD1 against surgery-induced memory loss (Terrando et al. 2013), 
possibly via FPR2. FPR2 immunoreactivity observed in the cerebellar cortex, 
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deep cerebellar nuclei and facial motor nucleus suggests that FPR2 may be 
involved in motor functions. A previous study showed that human FPR1 was 
densely stained in the cerebellum as well (Becker et al. 1998), suggesting that 
FPR1 and FPR2 may have similar roles for motor functions. Strong staining in 
the periaqueductal gray, brainstem and spinal cord is consistent with the 
involvement of FPR2 in modulation of pain (Abdelmoaty et al. 2013).
 Mouse Fpr-rs1 and Fpr-rs2 are structurally and functionally most 
similar to human FPR2 (Hartt et al. 1999). Fpr-rs1 was characterised in the 
sensory neurons of the vomeronasal organ (VNO), which is part of the 
olfactory system (Liberles et al. 2009; Riviere et al. 2009). Its functional role 
in the VNO is unclear, but the authors suggest that FPRs are potential 
chemosensory receptors in the olfactory bulb (Riviere et al. 2009). Therefore, 
it is possible that FPR2 in the rat olfactory bulb has similar functions to Fpr-
rs1 in the mouse VNO. The current study revealed FPR2 expression in the 
thalamus as well, suggesting a role of FPR2 in functions associated with the 
thalamus. The hypothalamic-pituitary-adrenal (HPA) axis comprises the 
hypothalamus, anterior pituitary and the adrenal cortex, and is a part of the 
neuroendocrine system that controls the adaptive response to stress (Smith and 
Vale 2006). A negative feedback mechanism exists whereby corticotrophin is 
released during stress and glucocorticoids, such as annexin I, suppress the 
release of corticotrophin, thereby maintaining homeostasis (Smith and Vale 
2006). A previous study postulated a role of FPR2 in the HPA axis where 
annexin I was suggested to act via Fpr-rs1 in the pituitary gland to inhibit 
release of corticotrophin in a mouse model (John et al. 2007). These findings 
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support a role of FPR2 in neuroendocrine functions that are crucial for 
maintaining homeostasis. 
 Electron microscopy images revealed FPR2 immunostaining in axon 
pre-terminals and dendrites in the prefrontal cortex. These pre-terminals 
contain synaptic vesicles but did not form mature synaptic contacts with 
dendrites. The results suggest that FPR2 may be present on immature axon 
terminals and synapses. Our findings of FPR2 localisation in neurons are 
consistent with previous studies which showed FPR2 expression in neurons in 
the mouse brain (Medeiros et al. 2013) and neural stem/progenitor cells 
isolated from the hippocampus of adult mice (He et al. 2013). Besides 
localisation in neuronal axons, FPR2 has also been localised in glial cells such 
as astrocytes in the mouse brain (Medeiros et al. 2013) and the rat spinal cord 
(Svensson et al. 2007), and primary microglia isolated from newborn mouse 
brains (Cui et al. 2002a). FPR2 is a receptor for RvD1, which has been shown 
to stimulate neurite outgrowth of primary murine dorsal root ganglion neurons 
(Shevalye et al. 2015). On the other hand, our observations that FPR2 is 
present on immature axon terminals suggest that it may be involved in neurite 
retraction. Although LXA4 and RvD1 have been shown to mediate their 
actions via FPR2, however, it is possible that these lipid mediators may be 
acting via other receptors in the CNS to mediate their actions. For instance, 
GPR32 is another known receptor of RvD1 and knockdown of GPR32 was 
found to reduce effects mediated by RvD1 (Krishnamoorthy et al. 2010). More 
studies are required to ascertain whether LXA4 and RvD1 mediate their 
effects through other GPCRs besides FPR2 or GPR32 in the CNS. 
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  The distribution of FPR2 in the CNS may give an insight into the 
mechanisms of anti-inflammatory and anti-nociceptive effects of LXA4 and 
RvD1. In a mouse model of traumatic brain injury, LXA4 was reported to 
reduce brain oedema, attenuate the expression of pro-inflammatory cytokines 
and increase FPR2 expression in astrocytes (Luo et al. 2013). In a rat model of 
subarachnoid haemorrhage, administration of LXA4 led to improvements in 
neurological functions and cognitive abilities such as learning and memory 
and knockdown of FPR2 by siRNA abolished these effects (Guo et al. 2016). 
It is likely that FPR2 is also involved in pain modulation. A possible role of 
FPR2 in neuropathic pain was also demonstrated when RvD1 was observed to 
reduce inflammatory pain behaviours in mice by normalising the spinal 
synaptic plasticity involved in pain hypersensitivity (Xu et al. 2010). More 
recently, LXA4 was demonstrated to reduce neuropathic pain associated with 
spinal cord injury (Martini et al. 2016). An important mediator is cPLA2, an 
enzyme which releases arachidonic acid from membrane phospholipids and is 
similarly highly expressed in the naïve brainstem and spinal cord (Ong et al. 
1999). Although immunohistochemical findings in chapter I showed mRNA 
expression but indiscernible protein levels of 15-LOX-1 in the brainstem and 
spinal cord of naïve rats, LOXs are known to be endogenously expressed in 
low basal levels (Conrad et al. 1992; Natarajan et al. 1997; Wuest et al. 2012). 
Under basal circumstances, cPLA2, 15-LOX-1 and FPR2 are endogenously 
expressed. cPLA2 releases arachidonic acid from membrane phospholipids 
which can be further acted upon by cyclooxygenase-2 (COX-2) to produce 
pro-inflammatory prostaglandins that increase neurosignalling (Moriyama et 
al. 2005). On the other hand, arachidonic acid can also be metabolised by 15-
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LOX-1 and 5-LOX to produce anti-inflammatory LXA4 that reduces 
neurotransmission (Wang et al. 2014; Miao et al. 2015). In an inflammatory 
state, the expression and activity of cPLA2 increases, generating increasing 
amounts of arachidonic acid from membrane phospholipids (Ong et al. 1999). 
15-LOX-1 is also induced during inflammation (Conrad et al. 1992; Wuest et 
al. 2012), therefore, the increased metabolism of arachidonic acid by 15-LOX-
1 would subsequently lead to higher amounts of anti-inflammatory LXA4. In 
view of the findings of high expression of FPR2 in the brainstem and spinal 
cord and its localisation on immature axon terminals, we hypothesise that 
LXA4 binding to FPR2 in the spinal cord causes retraction of immature axons 
which may decrease synaptic neurotransmission in the dorsal horn, thereby 
reducing pain and inflammation through its possible function as an 
endogenous anti-nociceptive signalling mediator. This mechanism is possibly 
similar to the retraction of immune cells from sites on inflammation by LXA4 
(Serhan et al. 1995; Fierro et al. 2003). Accordingly, spinal administration of 
LXA4 and RvD1 was demonstrated to reduce mechanical hypersensitivity and 
inhibit cytokine release in a mouse model of peripheral inflammation 
(Abdelmoaty et al. 2013). It could be possible that the anti-nociceptive effects 
of FPR2 ligands such as lipoxins (Abdelmoaty et al. 2013), resolvins (Xu et al. 
2010) and annexin I (Pei et al. 2011) in the spinal cord are mediated through 
FPR2. Overall findings suggest that FPR2 is likely to be involved in 
modulation of nociception.  
 In conclusion, the current study shows that FPR2 is highly expressed 
and distributed in the brain, with dense localisation in the hippocampal mossy 
fiber terminals, brainstem and spinal cord. Together, these findings 
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demonstrate that FPR2 is an important receptor for pro-resolving mediators in 
the brain which can aid in dampening damage caused by disease or injury. 
Results suggest an important role of arachidonic acid and DHA in the CNS 
due to their downstream products and their roles in neurotransmission. In 
addition, LXA4 and RvD1 may effect their anti-inflammatory roles and 






























 This thesis has focused on members of the arachidonic acid and DHA 
pathway that are involved in the production of anti-inflammatory and pro-
resolving lipid mediators LXA4 and RvD1, and their receptor FPR2.  
 In the first chapter, 15-LOX-1 was found to be the highest-expressing 
LOX isoform in the CNS, particularly in the forebrain. The prefrontal cortex 
was shown to express the highest levels of 15-LOX-1 mRNA. Further Western 
blot and immunohistochemical analyses showed high protein expression of 
15-LOX-1 in the forebrain as well. Electron microscopy showed that 15-LOX-
1 was localised in the dendritic spines of postsynaptic neurons and axons of 
presynaptic neurons. The distribution and localisation of 15-LOX-1 is useful 
for understanding its roles in the CNS. 15-LOX-1 metabolises DHA to 
produce lipid mediators such as RvD1 and neuroprotectin D1 which have been 
shown to be involved in synaptic plasticity, therefore 15-LOX-1 in the 
prefrontal cortex may contribute to synaptic plasticity associated with learning 
and memory. The high expression of 15-LOX-1 in the prefrontal cortex may 
be beneficial in neurodegenerative diseases as well as 15-LOX-1 metabolism 
of arachidonic acid and DHA produces LXA4 and RvD1, respectively, which 
are neuroprotective lipid mediators. Inhibition of 15-LOX-1 in the prefrontal 
cortex resulted in decreased RvD1 levels, which may affect prefrontal cortical 
processes that are mediated by RvD1, such as cognition. 
 The second chapter elucidates the differential epigenetic regulation of 
15-LOX-1 in fully differentiated primary neurons and undifferentiated SH-
SY5Y cells. Treatment with HDAC inhibitors revealed that 15-LOX-1 
expression is unaffected by epigenetic modifiers in primary neurons, whereas 





treatment of p300 HAT inhibitor or Tip60 HAT inhibitor with TSA and NaBT 
in SH-SY5Y cells showed that p300 HAT and Tip60 HATs are involved in 
15-LOX-1 transcription. Co-treatment of MTA with TSA showed that histone 
methylation can also regulate 15-LOX-1 expression. In addition, TSA caused 
death of SH-SY5Y cells through increased release of LDH; however, 
pretreatment with 15-LOX-1 inhibitor PD146176 did not significantly affect 
cell death mediated by TSA, suggesting that 15-LOX-1 is not involved in 
TSA-induced cell death. These findings suggest that 15-LOX-1 is highly 
sensitive to epigenetic influences in undifferentiated neurons compared to 
differentiated mature neurons. This may be attributed to the plasticity of the 
prenatal brain that is extremely sensitive to environmental influences which 
impose epigenetic marks on the genome. 
 The final chapter characterises FPR2, a multi-ligand receptor whose 
agonists include 15-LOX-1 products such as LXA4 and RvD1. Findings show 
that FPR2 is expressed and distributed evenly throughout the brain with high 
expression in the brainstem and spinal cord. The expression of FPR2 in the 
periaqueductal gray and spinal cord suggests that LXA4 and RvD1 may 
mediate their anti-nociceptive effects through FPR2. Electron microscopy 
revealed FPR2 is localised on immature axon terminals and dendrites of 
neurons. It is possible that when LXA4 and RvD1 bind to FPR2 in the spinal 
cord, they cause the retraction of immature axons which may decrease 
synaptic transmission and pain. The expression and distribution of FPR2 in the 






 In conclusion, the present study has examined and discussed key 
players of pathways involved in arachidonic acid and DHA metabolism, 
namely 15-LOX-1 and FPR2. High expression of 15-LOX-1 in the prefrontal 
cortex suggests possible involvement in synaptic plasticity, cognition and 
disease, together with products of PUFA metabolism such as LXA4 and RvD1. 
Epigenetic regulation of 15-LOX-1 strongly involves acetylation and 
methylation of histones and is limited to undifferentiated cells, whereas 15-
LOX-1 transcription is not susceptible to epigenetic modifications in primary 
neurons. This may be due to the plasticity of undifferentiated neurons in the 
developing brain which is highly vulnerable to environmental influences. This 
may lead to increased metabolism of DHA in undifferentiated and developing 
neurons, which aids in functional development of the brain. The 15-LOX-1 
products LXA4 and RvD1 are anti-inflammatory and neuroprotective lipid 
mediators in the CNS. The receptor for these lipids, FPR2, was found to be 
expressed in different parts of the brain and spinal cord, and may offer 
valuable insights into the effects of FPR2 ligands in the CNS, such as anti-
nociception. DHA is a critically important PUFA in the brain that is not only 
crucial for pre- and post-natal development, it is also beneficial for processes 
such as cognition and behaviour. 15-LOX-1 is a critically important enzyme in 
the brain due to its production of lipoxins, resolvins and neuroprotectins, 
which are beneficial for behaviour and cognition, as well as anti-inflammatory 
and neuroprotective lipid mediators that are useful for combatting 
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